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Pre-Clinical Development Of Aav Mediated Gene Therapy For Familial Lecithin
Cholesterol Acyltransferase Deficiency
Abstract
Familial lecithin cholesterol acyltransferase (LCAT) deficiency (FLD), is a rare monogenic disease,
characterized by abnormal lipid profile, corneal opacities, anemia and renal disease which progresses to
renal failure. There is currently no approved treatment for patients with this disease. FLD is a good
candidate for AAV mediated gene therapy but this therapeutic avenue has not been pursued until now.
Here, we completed dose response studies in LCAT KO and LCAT KO/ human ApoA-I transgenic mice
using AAV8 expressing human LCAT. AAV8-TBG-hLCAT induces significant increases in plasma %
cholesterol esterified at a dose as low as 3e9 GC per mouse, which is approximately equivalent to 1.5e11
GC per kg. We also characterize the first gain-of-function variant of LCAT ever to be identified, hLCATV114M. We expressed this variant in 293 cells via transient transfection and found that it has 150% the
activity of WT human LCAT. We also expressed this variant in mice using our AAV8 vector. In vivo,
AAV8-TBG-hLCAT-V114M induced greater increases in plasma lipids than AA8-TBG-hLCAT at the same
dose, and significant increase in plasma % cholesterol esterified was measured at 1e9 GC per mouse,
approximately equivalent 5e10 GC per kg. Additionally, we expressed four codon optimized variants of
human LCAT in vivo using AAV8. Codon optimization had little effect on the efficacy of hLCAT in mice,
with only one variant, AAV-TBG-hLCAT-v1, inducing greater increases in HDL-C than WT hLCAT. Lastly, we
were able to successfully induce renal disease in LCAT KO/SREBP1a transgenic mice using high-protein
diet. When we treated these mice with 1e10 GC of AAV8-TBG-hLCAT, we found that it neither prevented
nor reversed the progression of renal disease. Next, we will combine our gain-of-function LCAT, V114M,
with the leading codon optimized variant and evaluate this new ‘optimally effective vector’ as a clinical
candidate vector for use in a clinical trial.
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ABSTRACT

PRE-CLINICAL DEVELOPMENT OF AAV MEDIATED GENE THERAPY FOR FAMILIAL
LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY
Devin M. Christopher
Daniel J. Rader

Familial lecithin cholesterol acyltransferase (LCAT) deficiency (FLD), is a rare monogenic
disease, characterized by abnormal lipid profile, corneal opacities, anemia and renal disease
which progresses to renal failure. There is currently no approved treatment for patients with this
disease. FLD is a good candidate for AAV mediated gene therapy but this therapeutic avenue
has not been pursued until now. Here, we completed dose response studies in LCAT KO and
LCAT KO/ human ApoA-I transgenic mice using AAV8 expressing human LCAT. AAV8-TBGhLCAT induces significant increases in plasma % cholesterol esterified at a dose as low as 3e9
GC per mouse, which is approximately equivalent to 1.5e11 GC per kg. We also characterize the
first gain-of-function variant of LCAT ever to be identified, hLCAT-V114M. We expressed this
variant in 293 cells via transient transfection and found that it has 150% the activity of WT human
LCAT. We also expressed this variant in mice using our AAV8 vector. In vivo, AAV8-TBGhLCAT-V114M induced greater increases in plasma lipids than AA8-TBG-hLCAT at the same
dose, and significant increase in plasma % cholesterol esterified was measured at 1e9 GC per
mouse, approximately equivalent 5e10 GC per kg. Additionally, we expressed four codon
optimized variants of human LCAT in vivo using AAV8. Codon optimization had little effect on the
efficacy of hLCAT in mice, with only one variant, AAV-TBG-hLCAT-v1, inducing greater
increases in HDL-C than WT hLCAT. Lastly, we were able to successfully induce renal disease in
LCAT KO/SREBP1a transgenic mice using high-protein diet. When we treated these mice with

v

1e10 GC of AAV8-TBG-hLCAT, we found that it neither prevented nor reversed the progression
of renal disease. Next, we will combine our gain-of-function LCAT, V114M, with the leading codon
optimized variant and evaluate this new ‘optimally effective vector’ as a clinical candidate vector
for use in a clinical trial.
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CHAPTER 1: INTRODUCTION
Gene Therapy for Orphan Diseases
There are more than 7,000 rare or ‘orphan’ diseases, many of which are inherited
and severely disabling or life-threatening 1. In the United States, a disease is defined as
an orphan disease, if it affects less than 200,000 people. Together, these diseases affect
as many as 30 million Americans 2. Yet there are few therapies available for these
diseases. Partly, this is because each disease has its own unique cause and clinical
implications, requiring intense study and resources for therapeutic development,
perhaps for the benefit of only a few hundred or thousand patients worldwide. The
limited number of patients for many of these rare diseases also renders randomized,
placebo controlled trials challenging, so innovative and less common study designs must
be used in order to study the impact of new treatments. This limits the ability to gather all
of the information that is normally required by regulatory agencies for approval of a new
therapy. The small number of patients also limits the profitability of any new
pharmaceutical or biologic therapy, thereby discouraging research and development
related to these diseases within the pharmaceutical and biotech industries. Many rare
diseases may be good candidates for gene therapy given that many of them are genetic
diseases caused by a mutation in a single gene. With every new gene therapy trial, we
gain knowledge that will help us to successfully translate gene therapy from
experimental treatment to approved treatment. AAV gene therapy is now being studied
not only as a treatment for a specific disease, but also as a platform that is applicable for
the treatment of a wide variety of disorders.

1

To accelerate the development of therapeutics for orphan diseases, the Orphan
Drug Act was passed by congress in 1983. The Act promotes orphan drug development
in number of ways. Firstly, this piece of legislation established federal grants for
research programs focused on therapies for orphan diseases. Secondly, the Act awards
significant tax credits for clinical testing of orphan drugs and gives manufacturers market
exclusivity for 7 years 3. The Act also gives products with the Orphan Drug designation
accelerated FDA review, waiver of application fees and increased support and guidance
from the FDA. This avenue for assistance and accelerated approval has advanced the
development of new medicines for orphan diseases, with hundreds of new approved
therapies for orphan diseases since 1983. It is likely to be essential to the success of
the gene therapy field, which is highly targeted toward orphan diseases.
High Density Lipoprotein Metabolism
Cholesterol is required for many important cell and organ functions, including
proper cell membrane structure and steroid hormone synthesis 4. Cholesterol is
packaged into carrier molecules called lipoproteins for transport throughout the body.
Lipoproteins are complexes of lipids and proteins produced by the liver and come in a
variety of sizes, densities and compositions that serve a wide range of purposes,
including cholesterol transport 5. Briefly, chylomicrons, the largest and least dense
lipoproteins are responsible for the transport of dietary cholesterol from the intestines to
the liver, while very-low density lipoprotein (VLDL), intermediate density lipoprotein
(IDL), low density lipoprotein (LDL), lipoproteins with moderate density and size,
transport cholesterol from the liver to the extra-hepatic tissues for use by cells. The
smallest and most dense particle, high-density lipoprotein (HDL), is believed to transport
2

excess cholesterol from tissues back to the liver for excretion in a process known as
‘reverse cholesterol transport’ 6.
The majority of HDL subspecies are spherical in shape with a hydrophobic core
composed of cholesteryl esters (CE) and triglycerides (TG). The outer shell of the
lipoprotein is a phospholipid layer with free cholesterol (FC) and protein components.
The primary protein component of HDL is Apolipoprotein AI (ApoA-I). The immature HDL
subspecies, or pre-beta HDL, particles lack a hydrophobic core and are discoidal in
shape. These pre-beta HDLs are acceptors for FC being exported from extra-hepatic
tissues. As pre-beta HDLs accept more cholesterol and esterify it to cholesteryl ester
(see below) they become spherical in shape and progressively grow in size. HDL
cholesterol (HDL-C) is well known for its inverse association with cardiovascular disease
7,8

and is the reason that HDL-cholesterol (HDL-C) is colloquially referred to as “good

cholesterol”. However, several studies have failed to demonstrate a cardiovascular
benefit of raising HDL-C 9,10,11,12, bringing into question the causal relationship between
HDL-C and CVD. However, there is significant variation in particle size, composition and
function within the HDL class, therefore a measure of cholesterol composition is not a
good indicator of the functional abilities of these particles. The HDL field is now focused
on understanding in detail the metabolism and functions of this diverse class of
lipoproteins.
Lecithin Cholesterol Acyltransferase and Associated Deficiency Disorders
Lecithin-cholesterol acyltransferase (LCAT), is an alpha/beta hydrolase primarily
produced by the liver. This lipase is secreted into the plasma, where it catalyzes the
3

trans-acylation of the sn-2 fatty acid of lecithin to the free 3-OH group of cholesterol,
generating CE and lysolecithin 13. In the blood, LCAT preferentially binds to the surface
of HDL, where it is activated by ApoA-I, although the protein binds to LDL as well 14.
Following esterification, CE moves to the hydrophobic core of the lipoprotein, creating a
spherical particle, which accommodates additional cholesterol accumulation and
stabilizes the particle. By promoting the formation of mature HDL, LCAT is a key
enzyme that regulates HDL metabolism. HDL CE is removed from the blood through
two pathways. In one, it is selectively taken up by the liver via the SR-BI protein (REF).
In the other, it is transferred to apoB-containing lipoproteins in exchange for triglycerides
by the CETP protein (REF). It is believed that LCAT helps to drive the removal of
excess cholesterol from the body (Figure 1) 15. This pathway is referred to as reverse
cholesterol transport (RCT)16. RCT is a proposed mechanism by which HDL is
atheroprotective 17,18.
Although the basic structure of LCAT has previously been inferred by homology
modeling 19,20, the crystal structure of LCAT was solved by two independent groups in
201521,22. Structurally, the LCAT protein is divided into three domains, the alpha/beta
hydrolase domain which includes the active site, the membrane associating domain and
the cap, or lid, domain which contains the flexible lid loop that partially blocks access to
the active site. The catalytic triad of LCAT consists of Ser181, Asp345, and His377. The
N terminal region, located within the membrane associating domain, has been shown
previously to be important for interaction with ApoA-I 23,24, although other regions may
play a role as well 25.
There are two disorders associated with mutations in the LCAT gene 26. Familial
4

LCAT Deficiency (FLD), first reported by Norum, et al in Norway in 1967 27, is caused by
mutations which completely obliterate the function of the enzyme. The exact prevalence
of FLD is unknown, but as with many monogenic diseases, FLD is extremely rare and
most cases are identified within groups of closely related individuals. Family groups
carrying FLD mutations have been described in Norway 27,28, the United Kingdom 29
Poland 30, Japan 31,32, Iran 33, India 34,35, as well as a large number of families in Italy
36 37 38

, , . The disease is characterized by a near complete or complete lack of plasma

LCAT protein, extremely low plasma HDL-C (<10 mg/dL) , increased FC/CE ratio,
decreased apo-AI, elevated triglycerides (TG), normochromic anemia, corneal opacities
and the presence of an abnormal multilamellar, phospholipid rich particle called
Lipoprotein X (LpX) in the blood 39,40. Importantly, there is also a high prevalence of
chronic renal dysfunction in LCAT deficiency that may progress to renal failure, and is
the major cause of morbidity and mortality in patients with FLD 41,42 . Renal disease
presents as albuminuria as early as the teenage years and progresses to renal failure by
the third or fourth decade of life. It is believed that esterification of plasma cholesterol by
LCAT is necessary for preventing the accumulation of free cholesterol (FC) in the blood
and extra-hepatic tissues 43. Accumulation of excess free cholesterol disrupts the cell
membrane and causes toxicity in affected cells, presumably leading to the renal disease
through an ill-defined mechanism.
The second disorder associated with mutations in the LCAT gene, is Fish Eye
Disease (FED). FED was originally described by Carlson et al in Lancet in 197844. The
disease was so named because of the resemblance of the patient’s eyes to the eyes of
boiled fish. The classic presentation of FED described in the first four patients in the
5

Lancet publication, is corneal opacities, low plasma LCAT mass, low HDL-C, high LDLC, normal plasma FC:CE ratio, and elevated TG levels.. Importantly, FED is not
associated with anemia, LpX or renal disease. As discussed below, the defect in LCAT
in FED is not as severe, suggesting that even modest LCAT activity can prevent the
most severe complication of FLD, namely the progressive renal disease.
LCAT Mutations in FLD and FED
It is generally believed that FLD and FED are caused by distinct sets of
mutations 26. A number of FLD mutations are frameshift or nonsense mutations which
are strongly predicted to disrupt the production of the functional protein product

42,45

. This

is consistent with the observation that patients have extremely low, sometimes
undetectable plasma LCAT mass and a complete loss of LCAT activity. But there are
also many missense mutations that cause FLD. Many of these missense mutations are
clearly predicted to disrupt the function of important structures within the LCAT protein,
such as the active site or core of the hydrolase domain, the lid or substrate binding
regions. FLD mutations are spread out across the entire coding sequence.
While FLD is caused by mutations which completely eliminate the function of
LCAT, it is generally understood that FED is caused by mutations which alter or partially
ablate the function of the enzyme 46. In 1985, Carlson et al demonstrated that plasma
from an FED patient lacked the ability to esterify cholesterol on HDL particles (referred to
as alpha-activity)47. At this time, it was assumed that this FED LCAT retained its activity
on LDL (referred to as beta-activity) but this had not been tested. However, this
hypothesis was indeed confirmed to be true of another FED mutation, which was found
6

in two patients and published in 1991, by Funke et al 48. Overall, evidence suggests that
FED is caused by mutations that specifically eliminate LCATs ability to esterify
cholesterol on HDL, while leaving its activity on LDL intact. However, this has not turned
out to be true of all FED cases 45,49.
So called ‘FED mutations’ are typically missense mutations, a change of a single
amino acid that reduces (but does not completely eliminate) the activity of LCAT. FED
mutations are spread out across the entire linear LCAT sequence, but small clusters of
FED mutations are located near the N-terminus and C-terminus within the hydrolase
domain of LCAT. Most FED mutations are located on the exterior of the protein. In
addition, based on their locations, most FED mutations are not predicted to significantly
alter important elements of the enzyme. Presumably, these mutations affect the
interaction of LCAT with ApoA-I and/or HDL without significant impact on the overall
protein structure. However, not all FED mutants fit this description: Klein et al. identified
a single codon deletion (L300) in a patient presenting with corneal opacities, low HDL-C
and triglyceridemia 47. This unique mutation is also an example of a patient with FED
who has normal alpha-activity, LCAT activity on HDL, inconsistent with the hypothesis
that FED is caused purely by a loss of alpha activity.
In any case, although the clinical presentation of patients with LCAT mutations
can be neatly grouped into the two categories, the classification of LCAT mutations does
not appear to be as simple as the difference between a complete loss of activity and a
loss of alpha-activity. However, it is important to note that FED patients, who can have
half or less than half of normal plasma LCAT activity, do not have renal disease.
Similarly, heterozygote carriers of FLD mutations, who have half of normal plasma LCAT
7

mass and reduced LCAT activity, are by all other accounts normal. This indicates that
half of normal plasma LCAT mass is sufficient to prevent any signs of disease. This is
encouraging for the field of gene therapy, as it is possible that a very low concentration
of enzyme may be therapeutic for patients with FLD.
Lipoprotein X
LpX is an abnormal multilamellar vesicular particle and is one of the defining
sequelae of FLD. LpX is composed of a phospholipid and free cholesterol layer with an
aqueous center rich in albumin. The particle is large in size with a diameter of
approximately 70-90 nm, roughly the size of the lipoprotein VLDL. While LpX is a
hallmark of FLD, it is not unique to FLD. LpX is also found in patients with severe chronic
cholestasis, such as caused by liver disease or inherited disorders like Alagille
Syndrome 50, and has been seen in patients with other lipid disorders as well 51. For
many years, it has been thought that LpX is the cause of renal disease in FLD. It has
been known since the late 1990’s that LpX is taken up by mesangial cells (resident
phagocytic cells in the kidney that play an important role in inflammation and fibrosis) in
culture, and that it activates inflammatory pathways in these cells 52,53. Recently, Ossoli.
et al demonstrated that injection of recombinant LpX was sufficient to induce renal
lesions and albuminuria in LCAT KO mice, while injection into LCAT competent mice has
no effect on renal structure or function 54. The investigators showed that LpX disrupts the
glomerular basement membrane, induces podocyte effacement and expansion of the
mesangial cell layer, all of which are consistent with histologic changes seen in FLD. In
the presence of LCAT, LpX was remodeled into an HDL-like particle containing ApoAI.
Consistent with this finding, children with Alagille Syndrome also present with renal
8

disease that is histologically similar to FLD. It is thought that LpX does not pass through
the glomerular filtration slits as the diameter of these slits is approximately 40nm,
significantly smaller than the average size of LpX particles, but exerts its nephrotoxic
effect via complex signalling pathways initiated by association with the glomerular
basement membrane.
Therapies for FLD
At this time, there are no FDA approved treatments for FLD. Patients are
managed symptomatically. Low-fat diets or statins have been suggested in order to
lower total plasma cholesterol, but there are no studies to confirm their efficacy in
preventing or slowing the development of renal disease 55. Dialysis is required once
patients develop renal failure. FLD patients are candidates for kidney transplant but
ultimately the disease recurs in the transplanted organ 256,57. Likewise, corneal
transplantation may be an option for patients who are severely impaired, but the disease
also recurs 58.
Recombinant LCAT replacement therapy administered intravenously is in
development as a therapy for FLD. Results of a Phase I clinical trial, in patients with
coronary heart disease (CHD) (but not LCAT deficiency), were published in 201659. In
this trial, 16 subjects with stable CHD were treated with a single infusion of one of four
doses of recombinant LCAT (rLCAT). The three highest doses successfully increased
HDL-C in these patients by 6%, 36% and 42% respectively. Recombinant LCAT was
found to have a half-life of approximately 42 hours. There were no serious adverse
events in this trial. The enzyme was deemed safe and effective at increasing HDL-C in a
9

dose dependent manner. In addition, a single FLD patient was treated with recombinant
enzyme therapy weekly over a period of 8 months. Recombinant enzyme therapy was
shown to improve anemia, plasma lipid profile and renal function in this patient

60
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success of these studies is encouraging, and suggests that a gene therapeutic approach
to ‘replacing’ LCAT through hepatic gene transfer and expression may be a feasible
approach to therapy for FLD.
Adeno Associated Virus
Adeno Associated Viruses (AAV) are a class of small, non-enveloped viruses first
discovered as a contaminant in adenovirus preps in 1965 61. This virus is unusual in that
its genome does not encode all of the necessary components to replicate on its own.
Because of this, AAV must be accompanied by another virus which provides the
required enzymes for DNA replication and propagation. AAV has not been associated
with any human disease, although natural infection does occur and most people have
pre-existing antibodies against these viruses 62. This group of viruses is diverse with
more than 100 distinct serotypes identified so far 63. Each serotype has a distinct capsid
with a unique tropism. For example, AAV8 is a well-studied serotype that heavily targets
liver while AAV1 targets muscle tissue more efficiently 64. Although the packaging
capacity of these viruses is small at less than 5kb, these properties make AAV a
uniquely safe and versatile vector for human gene transfer. AAV has been widely
studied as a gene transfer vector and is the gene therapy vector of choice in many
ongoing clinical trials for rare monogenic diseases 65,66,67,68
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AAV Gene Therapy for Hemophilia
While gene therapy, the treatment of a disease by the introduction of an
exogenous gene, has been the subject of much interest for many decades. Only recently
has it become a reality. Hemophilia is a relatively common monogenic clotting disorder
caused by mutations in a gene encoding one of two important clotting factors: factor VIII
(hemophilia A) or factor IX (hemophilia B). Mutations that severely impair the function of
these clotting factors prevent the formation of blood clots, resulting in spontaneous
bleeding which can be life threatening. Patients are treated via IV infusion of either
recombinant or plasma derived clotting factor, two to three times per week
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of hemophilia with plasma derived enzyme has been used since the 1960s. By the
1980s most hemophilia patients had acquired Hepatitis C and/or HIV from contaminated
plasma-derived enzyme 70. Stricter screening protocols and production methods were
implemented in the 1980s and were successful in preventing viral contamination.
Regardless, the field was revolutionized with the approval of recombinant enzyme
therapy in the early 1990s. However, whether recombinant enzyme or plasma derived
enzyme is used, the treatment is burdensome and expensive, requiring infusions once,
twice sometimes three times per week and costing around $300,000 USD per year 71. In
contrast, gene therapy for hemophilia has the potential to be curative, or at least provide
clinical benefit lasting for many years after a single treatment, reducing or eliminating the
need for weekly or bi-weekly clotting factor infusions. Gene therapy, if approved, would
also be the best option for patients residing in less developed countries where
healthcare is poor and weekly enzyme treatments are not available 72.
In many ways, hemophilia is a logical candidate for AAV gene therapy. The
11

coding sequences for Factors VIII and IX are relatively short and are within the AAV
packaging limits, with Factor VIII being near capacity making hemophilia A a more
difficult target. AAV8 is a well-studied vector and known to be good for liver
transduction. Factors VIII and IX are secreted proteins with a very low plasma
concentration in normal individuals (200-5,000 ng/mL), requiring only a small amount of
expression to alleviate the severe phenotype. AAV gene therapy for hemophilia is
arguably one of the most successful gene therapies in development right now in the
United States. At least 3 different clinical trials using AAV vectors have successfully
treated patients with hemophilia. The long-term outcomes of one of these trials was
published by Nathwani. et al. in 201447. Nathwani et al. used a self-complementary
AAV8 vector expressing a codon-optimized Factor IX to treat 10 men affected with
Hemophilia B. The investigators found that FIX expression was dose dependent and
stably expressed for a median of 3.2 years after treatment. Most of the patients were
able to reduce the frequency of enzyme infusions. Four patients, one in the low dose
group (2×1011 vector genomes per kg), one in the intermediate dose group (6×1011
vector genomes per kg) and two in the high dose group (2×1012 vector genomes per
kg), were able to discontinue enzyme replacement therapy completely. Gene therapy
reduced the amount of enzyme used by this group of patients by 92% during the year
following treatment. Bleeding episodes also decreased by 90%. Elevation of liver
enzymes 7-10 weeks after treatment was the only significant study related adverse
event and was controlled with a short course of prednisone. This trial successfully
demonstrated a decrease in the primary cause of morbidity and mortality for this disease
(bleeding episodes), and showed clear benefit in these patients even in the absence of
curative treatment. While it is still unknown what the financial cost of gene therapy for
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the patient will be, there are clear advantages of gene therapy as compared to enzyme
replacement therapy. Despite the encouraging results of this trial, and others like it, there
are still no approved gene therapies in the United States.
Importance of the Dose
One of the most important parameters in the pre-clinical and clinical development
of gene therapy is the therapeutic dose. A common way to express the therapeutic dose
is the minimal effective dose (MED). The MED is defined as “the lowest dose level of a
pharmaceutical product that provides a clinically significant response in average efficacy,
which is also statistically significantly superior to the response provided by the placebo”
. A “clinically significant response” is open to interpretation and can be defined as a
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change in any given parameter that is relevant to the disease of interest. Defining the
MED of an AAV in small animal studies is an important first step. This helps to
understand the likelihood of a clinical benefit in humans as well as understand if the
scale of the dose is reasonably achievable in a human patient.
A major concern with gene therapy, particularly gene therapy using viral vectors,
is the development of immunity against the vector and/or immunity against the
transgene. Mingozzi et al. demonstrated that the likelihood of T-cell responses directed
against the AAV capsid increases with the dose of vector used 74. T cells that recognize
the AAV capsid or the transgene can wipe out transduced cells and reduce or eliminate
expression of the transgene. And since humans will develop antibodies against the AAV
vector once exposed, a second gene therapy attempt will not be effective. Therefore, it is
essential to keep the therapeutic dose as low as possible to keep the risk of immune
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response as low as is reasonably achievable 75,76. In addition, a lower MED means less
vector is required for treatment, which has substantial implications for manufacturing.
This reduces the burden of vector production and ultimately will reduce the cost of the
therapy.
Glybera and the Utility of Naturally Occurring Gain-of-Function
In 2012, Glybera was approved for sale by the European Medical Agency and
became the first gene therapy to be approved by regulatory agencies in the western
world 77,78. Glybera is a gene therapy product for the treatment of the rare monogenic
disease lipoprotein lipase (LPL) deficiency. LPL is an enzyme secreted by skeletal
muscle and is essential for the metabolism of chylomicrons 79. Without functional LPL,
patients with LPL deficiency develop life threatening episodes of pancreatitis caused by
the accumulation of triglycerides in the body. The developers of Glybera chose adenoassociated virus serotype 1 (AAV1) as the in vivo gene delivery vector. AAV1 has good
transduction in skeletal muscle, making it an appropriate serotype for this disorder. For
the treatment of LPL deficiency, the investigators chose a naturally-occurring gain- offunction variant of human LPL (LPLS447X) to be used as the transgene. This gain-offunction variant has higher activity in vivo than WT LPL 80 . AAV2-LPLS447X was tested
in both murine and feline models of LPL deficiency before moving to clinical trials. In
clinical trials, the highest dose tested was 1x1012 genome copies (GC) per kg of
bodyweight. One year after treatment, some subjects demonstrated improvements in
chylomicron metabolism. Despite a lack of evidence for efficacy in preventing
pancreatitis (the primary cause of morbidity and mortality in LPL deficiency), Glybera
was approved for use in humans by the European Medical Agency in November of 2012.
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The choice to use a naturally occurring gain-of-function variant, like the makers
of Glybera, has two major advantages. First off, the use of a high activity variant in place
of WT, reduces the dose of AAV required for a therapeutic effect. Secondly, because
this variant already exists in nature, it is assumed that there should not be any severe
detrimental effect when this variant is substituted for WT, i.e. the creation of a new
epitope that induces a dangerous immune response. This ‘natural’ advantage, eases
safety concerns relative to using an engineered gain-of-function variant.
Human Genetic Studies and the Identification of LCAT-V114M
Large scale human genetic studies such as genome wide association studies
(GWAS) are a powerful way of gathering information about human health and disease
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These studies, which profile common variants in the genomes of tens or hundreds of
thousands of people, examine the relationships between single nucleotide
polymorphisms (SNPs) and specific biological traits. SNPs with a strong association to a
trait of interest can then be investigated to determine the mechanism of the association,
which may inform the risk of disease, disease processes and/or identify therapeutic
targets. GWAS studies may be particularly important for understanding the causes of
complex diseases, such as cardiovascular disease or obesity, which often have a large
number of contributing genes or traits 82, 83. While human genetic studies are widely
applicable to complex disease, although less common, the information gained in these
studies can also be applied to monogenic diseases. While a single gene may be causal,
such as the case with FLD and FED, other genes (SNPs) may modify disease
progression and outcomes 84. The biological effect of relatively common SNPs located
in or near the gene of interest is likely to be less severe than the effect of more rare
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mutations which cause the disease in question, but nonetheless, these SNPs and their
more subtle biological effects, tell us something about the biology of the gene or the
protein and this information may be leveraged to design rational therapeutics.
In these studies, we have leveraged data from human genetic studies to identify
a therapeutic candidate. Human genetic studies have identified three variants of human
LCAT that are associated with significantly altered plasma lipids. Two variants, R123H
and S232T are associated with lower HDL-cholesterol in the heterozygous state (Table
1). The third variant, V114M is associated with higher HDL-cholesterol, was first
identified in a study by Cohen et al. in 2004 85. Cohen et al. sequenced three candidate
genes, one of which was LCAT, in people with HDL-C in the upper or lower 5% of the
population. LCAT-V114M was the only LCAT variant associated with higher HDL-C. The
authors predicted the effect of the substitution to be benign. In our studies, we
characterized this variant, LCAT- V114M, the first gain of function variant of LCAT to
ever be identified.
Codon Optimization
The concept of codon optimization has been used previously in the gene therapy
field to ultimately reduce the dose of vector required 86. Important to the method of codon
optimization is the degeneracy of the genetic code, or the ability of several different
codons to encode for the same amino acid. This means that many different DNA and
RNA sequences can encode an identical protein with an identical amino acid sequence.
While there are as many as four codons for a single amino acid, not all codons are
‘created equal’. It is known that some codons are translated more efficiently than others,
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and the relative efficiency with which each codon is translated may differ between
species, and even different tissues within a single organism

87,88

. These differences in

efficiency, or speed with which a protein is translated from its respective RNA, is
hypothesized to be due, at least in part, to differential tRNA availability. tRNAs
themselves may be translated and/or expressed at different rates and ultimately the
number of a specific tRNAs available will also depend on the frequency of its codon in
the local environment 89. This means that in each cell type, depending on the genes
being expressed, and depending on the expression patterns of the different tRNAs,
some codons may be better than others in terms of the speed of translation 90. This
knowledge can be exploited through the rational design and testing of different DNA
sequences, which may not share high sequence identity, but encode the identical amino
acid sequence.
Codon optimized sequences have been utilized in preclinical studies of gene
therapy for hemophilia 91, Rett Syndrome 92, cancer 93, glycogen storage disease type
1a94, ornithine transcarbamylase (OTC) deficiency 86 and others, as well as in studies of
DNA vaccines for HIV 95. However, in almost all cases, only a single variant was tested
and in many cases this variant was not directly compared with the WT sequence.
Mellitzer et al. in 2014, directly compared 48 sequences, encoding an identical protein
product, in this case, the enzyme Trichoderma reesei cellobiohydrolase 2 (TrCBH2) 96.
The researchers found that there was wide variation in the expression of the TrCBH2
from these different sequences, ranging from almost undetectable expression to levels
double that of the WT sequence. It has also been noted, that the expression of a large
number of genes (as many as 30%) are not significantly affected by codon optimization,
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and depending on the algorithm used to design the sequence, results are variable 97.
Altogether, this suggests that a series of candidate sequences should be tested in order
to identify the variant that expresses the best 98. If codon optimization proves to be
effective for a gene of interest, it may be a very useful strategy, particularly in the field of
gene therapy.
Animal Models and Translation to the Clinic
Preclinical testing of a candidate therapy in an animal model is an essential step
in the translation of that therapy into the clinic. While technically not required, the
demonstration of important principles in an animal model provides regulatory agencies
with invaluable information about the potential risks and benefits of the candidate
therapy 99. In reality, regulatory approval to test a therapy in clinical trials without first
testing in an animal model, is quite impossible. Testing in multiple species, particularly a
large animal model such as non-human primates, is desirable, as the biological systems
of a single species may not necessarily be representative of human patients
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However, with rapid improvements in DNA technologies it is now possible to create
animal models, particularly mice, which are very human-like in certain aspects of their
biology. However, just because a mouse is ‘humanized’ does not mean that it will
accurately recapitulate all the features of a human disease, so models must be chosen
carefully to answer specific questions and study endpoints must also be cautiously
selected if one expects the information gained to be relevant to clinical outcomes.
A mouse with a comparable genetic defect as patients with the human disease
may not be adequate as a model. For instance, LCAT KO mice, which have an exon
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deletion preventing the production of any measureable LCAT protein have extremely low
HDL-C, similar to humans with FLD. However, without any additional intervention, the
mice do not recapitulate any of the other features of the human disease 101. LCAT KO
mice do not have LpX, anemia, corneal opacities or any reduction in renal function. This
may be due to differences in lipoprotein metabolism between mice and humans. For
example, mice lack the enzyme cholesteryl ester transfer protein (CETP) which in
humans, moves TG from LDL, or VLDL, to HDL, and exchanges CE from HDL to LDL, or
VLDL, in return 102. This may be particularly relevant in the setting of LCAT deficiency as
CETP is responsible for the redistribution of CE amongst the different lipoprotein
classes. Since mice lack CETP, CE redistribution does not occur. Another potential
explanation for the lack of a disease phenotype in LCAT KO mice is a difference in diet.
Lab mice are typically maintained on a ‘chow’ diet which is very low in cholesterol, not at
all representative of the average human diet. On chow diet, these mice may simply not
have enough available cholesterol to accumulate in tissues. In fact there is some
evidence for this hypothesis, which will be discussed in Chapter 5.
Regardless of the reason why LCAT KO mice differ from LCAT deficient humans
so dramatically, without a model that demonstrates the important features of FLD, we
cannot measure the potential clinical impact of a new therapeutic. In addition, the
mechanism of renal disease in FLD is still not fully understood, making it even more
difficult to create an animal model with mechanistically comparable disease. During preclinical studies, one must think forward to a clinical trial and consider what the clinical
endpoints will be. Those clinical endpoints (or an appropriate surrogate) should be
measureable in an animal model and one should be able to demonstrate a benefit of the
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therapy based on those endpoints. As we currently do not have an animal model for FLD
that will allow us to measure clinically relevant endpoints, such as improvements in renal
function, the development of such a model will be absolutely essential in order to
complete the necessary pre-clinical studies.
In the studies outlined in this document, we will be expressing human LCAT in
mice using AAV8. We have chosen to study human LCAT as opposed to mouse LCAT
as this will be the same vector and transgene combination used in a clinical trial. It is
important to note that the interaction between LCAT and its cofactor ApoA-I is species
specific: human LCAT is not activated by mouse apoA-I as effectively as it is activated
by human ApoA-I 103 This species specificity was also shown in previous work performed
by our lab, with human LDL-receptor and its cofactor, Apolipoprotein B (ApoB)104. For
this reason, we chose to test our vectors in both LCAT KO mice and LCAT KO/hApoA-I
transgenic mice
Goals of the Dissertation
We believe that FLD is a promising candidate for AAV gene therapy for a number
of reasons. Firstly, the disease is inherited, monogenic and severe in nature. Renal
failure in FLD is the primary cause of morbidity and mortality, and there is a need for
treatment, as there are no existing therapies. Although recombinant enzyme therapy is
up and coming for FLD, gene therapy has the potential to reduce or eliminate entirely the
need for costly and time consuming enzyme infusions, potentially for entirety of the
patient’s life. Secondly, LCAT is a small protein, with a coding sequence of only 1.7kb,
thus the full length LCAT will easily fit into an AAV vector. AAV8 is well studied and
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widely used for liver transduction. Other liver directed gene therapy trials have had good
success. Similar to hemophilia, LCAT is a liver secreted protein with a low plasma
concentration in normal individuals, suggesting that the dose of AAV required to express
a therapeutic level of protein is likely relatively low. In addition, the measurement of
LCAT in plasma is technically easy to perform and non-invasive.
Existing human genetic data suggests that hLCAT-V114M is a naturally
occurring gain-of-function variant of LCAT. In these studies, we characterize this variant
and determine that it is indeed a naturally occurring gain-of-function variant of LCAT.
This variant will likely be extremely useful as a substitute for WT LCAT, for use in either
recombinant enzyme therapy or for gene therapy.
The overall goal of this dissertation was to complete essential steps in the preclinical development of a novel gene therapy, with the goal of preparing for a clinical trial
to test the clinical candidate gene therapy vector as a treatment for FLD. We have
broken down this goal into two primary aims. The first aim was to develop an optimal
vector that would express a ‘therapeutic’ level of an ‘optimized’ LCAT transgene at the
lowest possible dose of vector and to determine the MED of this ‘clinical candidate’ AAVLCAT in a humanized mouse model such that we can reasonably infer a starting dose
for a clinical trial. In our quest to find the optimal transgene, we examined LCAT-V114M,
the first naturally occurring gain-of-function variant of LCAT to ever be identified, as well
as four codon optimized variants of hLCAT. The second aim was to establish an animal
model of FLD renal disease that could be used to demonstrate that our clinical candidate
could prevent or slow the development of renal disease

21

Fig 1. The biochemical reaction of Lecithin Cholesterol Acyltransferase (LCAT).
The enzyme LCAT performs a two step reaction. The first step is the cleavage of the sn2 fatty acid from a molecule of lecitihin. This fatty acid chain is then transferred to the
free hydroxyl group of a free cholesterol molecule to form a hydrophobic cholesterol
ester.
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Fig 2. LCAT promotes removal of cholesterol from extrahepatic tissues via
formation of mature HDL particles. Dietary cholesterol is secreted by the liver in the
form of VLDL. In the plasma, VLDL is transformed into LDL which can be taken up by
extrahepatic tissues. Any excess free cholesterol (FC) in extrahepatic tissues is
transferred to pre-beta HDL for transport back to the liver for excretion. The enzyme
LCAT esterifies FC on HDL, a process that is important for the maturation of these
particles such that they can be removed by the liver and excess cholesterol can be
excreted as bile. Thereby, without functional LCAT, excess free cholesterol accumulates
in the plasma and extrahepatic tissues.
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CHAPTER 2: PRE-CLINICAL DEVELOPMENT OF A CLINICAL
CANDIDATE FOR AAV BASED GENE THERAPY FOR FLD
Abstract
We believe that Familial LCAT Deficiency (FLD) is a good candidate for AAV
gene therapy for a number of reasons. Until now, gene transfer of human LCAT using
adeno associated virus, has not been examined as a therapeutic for FLD. Here we
complete several essential steps in the selection of the clinical candidate vector for a
clinical trial. First, we identified the minimally efficacious dose (MED) of our WT human
LCAT AAV vector in LCAT KO and humanized LCAT KO/hApoA-I transgenic mice. Then
we characterized a naturally occurring gain of function variant of human LCAT, V114M,
that has approximately 160% the activity of WT. This variant is the first gain-of-function
variant of LCAT ever to be identified. We then determined the MED of a vector
expressing this variant. hLCAT-V114M reduced the MED of our LCAT vector from 3e9
GC per mouse to 1e9 GC per mouse. Lastly, we directly compared four codon optimized
variants of our human LCAT, in the hope of identifying a variant that will further increase
the effectiveness of our vector and decrease the MED. We intend the combine the
sequences of best codon optimized variant, hLCAT-v1 with our gain-of-function V114M
to create the clinical candidate vector that will be tested in a first clinical trial.

24

Introduction
A major aim of my thesis was to develop an optimal AAV vector that would
express a ‘therapeutic’ level of an ‘optimized’ LCAT transgene at the lowest possible
dose of vector and to determine the MED of this ‘clinical candidate’ AAV-LCAT in a
humanized mouse model such that we can reasonably infer a starting dose for a clinical
trial. This work represents the first known testing of an AAV vector expressing human
LCAT (AAV-hLCAT) in LCAT KO mice. It is unknown what dose of AAV-hLCAT will be
sufficient to normalize plasma lipids or FC:CE ratio in LCAT deficient mice. Previous
studies in our lab and others, have performed in vivo mouse studies with AAV-hLCAT,
although with only a single dose and only in LCAT competent mice. In previous work
done in our lab, hApoAI transgenic mice, were injected with 1e12 GC of AAV-hLCAT,
either alone or combined with AAV-hCETP. 1e12 GC of AAV-hLCAT induced a 6 fold
increase in plasma LCAT activity and a 10 fold increase in plasma HDL-C, relative to
baseline, and expression of CETP improved RCT in these mice 96. In 2011, Chen et al.
at Merck Research Labs, injected human CETP transgenic, LDL-receptor heterozygous
mice with a dose of 1e12 GC per mouse of AAV-hLCAT 105. At this dose, mice
demonstrated a 3 fold increase in plasma HDL-cholesterol and a significant decrease in
LDL-cholesterol. While the work done in both studies demonstrate the strong effect of
AAV-hLCAT, these experiments were all performed in LCAT competent animals at a
high dose of AAV, a dose which is typical for overexpression studies. As mentioned
above, determination of the dose to be used at the start of a clinical trial is an important
step in preclinical development. This, the determination of the MED of AAV8-TBGhLCAT in LCAT KO and humanized LCAT KO/hapoA-I transgenic mice, was the first
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goal of my dissertation, and is the first goal of this chapter.
The second goal of this chapter was to characterize this naturally occurring gainof-function variant of LCAT, LCAT -V114M. We set out to evaluate this variant as the
potential transgene for our clinical candidate vector. Similar to AAV8-BG-hLCAT (WT),
first we determined the MED of the AAV8-TBG-hLCAT-V114M vector. Secondly, we
tested the ability of this variant to normalize the lipid profile of an FLD patient. Lastly, we
addressed the putative mechanism of gain of function in this variant.
The last goal of the research outlined in this chapter was to examine four codon
optimized variants of human LCAT to determine if we could further lower the MED of our
vector using this strategy. Codon optimization of the LCAT gene has not yet been
studied. It is unknown how optimization will affect expression of this gene. In addition,
there are very few studies directly comparing the effect of different codon optimized
variants of the same gene. Here we compared four different DNA sequences with
approximately 60% identity that express an identical WT human LCAT.
Results
Dose response of AAV8-TBG-hLCAT in LCAT KO Mice
As stated, our first goal was to determine the MED of AAV8-TBG-hLCAT in
LCAT KO mice. For the purposes of these studies, the MED will be defined as the lowest
dose that produces a significant increase in plasma percent cholesterol esterified (%CE).
We estimated the starting dose for our studies based on the doses used in human trials
for other diseases. For reference, the therapeutic dose of Glybera 77, the only gene
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therapy product approved in western medicine, and also an AAV based therapy, is 1e12
GC per kg of bodyweight, which is approximately equivalent to 3e10 GC per mouse. In
the hemophilia trials, the starting dose of AAV was 2e11GC per kg (4e9 GC per mouse)
and the highest dose was 2e12 GC per kg (4e10 GC per mouse) 68. Based on these
doses, we believed that our MED would be somewhere in the range of 3e9 to 3e10 GC
per mouse.
I injected LCAT KO mice (N=4) with our AAV8 with human WT LCAT under the
control of the thyroxine-binding globulin (TBG) liver specific promoter, produced by Penn
Vector core. For our first experiment, we started with three low doses of vector, 1e9, 3e9
and 1e10 GC per mouse. Control mice were injected with 1e10 GC per mouse of AAVNull. We measured total cholesterol (TC) and HDL-cholesterol (HDL-C) in these mice.
Prior to injection, LCAT KO mice have low TC, less than 30 mg/dL with 90-100 mg/dL
being normal, and very low HDL-C, typically below 5 mg/dL as compared to 65-75 mg/dL
in a normal mouse. After injection, mice that received a dose of 1e10 GC did have
increases in both TC, at 4 weeks post injection with 45±12mg/dL, and HDL-C of 22±13
mg/dL, though these differences were not statistically significant in this experiment
(Figure 3A and 3B). All mice in the 1e9 GC and 3e9 GC groups had lipids comparable
to baseline. Lipids in the high dose group increased slightly until week 4 and then were
stable out to 12 weeks post-injection.
As we did not see any statistically significant differences in this first experiment,
for the second experiment I tested two higher doses of AAV-hLCAT, 3e10 and 1e11 GC
per mouse (N=5). I also injected a group of mice with 1e10 GC each, for comparison
with the previous experiment. As in the previous experiment, a control group was
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injected with AAV-Null, this time at a dose of 1e11 GC per mouse. Both the middle and
high dose groups in this experiment demonstrated statistically significant increases in TC
and HDL-C (Figure 4A and 4B). The high dose 1e11 GC group had a mean TC of
116±18mg/dL and HDL-C of 90±8 mg/dL, both values being above the normal range.
The middle dose group, at 6 weeks post injection, had a mean TC of 118±12mg/dL
nearly identical to the high dose group.HDL-C in the middle dose group was lower at
60±7 mg/dL. The low dose group (1e10GC) was comparable to the previous experiment
in that the mean TC was about 50 mg/dL but was not significantly different from nullinjected control mice. Phospholipids in these mice followed a similar dose dependent
pattern (Figure 4C). No increase was seen in plasma ALTs in these mice (Figure 4D).
All three AAV-hLCAT groups had percent plasma percent cholesterol esterified
within the normal range at approximately 75% (Figure 5A). Whole plasma cholesterol
esterification rate (CER) in these mice was variable, but overall tended to increase
consistent with the dose (Figure 5B). Only the highest dose group had CER that was
statistically significantly different from null injected mice. To examine cholesterol
distribution and particle size we separated pooled plasma samples by FPLC (Figure 4C).
When we measured TC in these samples we see a dose dependent increase in the HDL
peak, with higher doses skewing towards a larger particle size (towards the lower
fraction numbers). This is consistent with an increase in mature HDL. Based on these
experiments, we determined the MED of AAV-hLCAT to be 1e10 GC per mouse, which
is approximately equivalent to 5e11 GC per kg, which falls right in the middle of the
range that we predicted.
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Dose response of AAV8-TBG-hLCAT in LCAT KO/hApoA-I transgenic mice
ApoA-I is the primary protein component of HDL and is a potent activator of
LCAT. It is known that human LCAT is activated more efficiently by human ApoA-I than
its murine counterpart 103. This species-specific preference is to be expected and may be
the explanation for the difference between the responses to AAV-hLCAT in the two
studies outlined in the Introduction to Chapter 2 above. Even though both studies used
the same dose in LCAT competent animals, AAV-hLCAT injected LDLr
heterozygous/CETP transgenic mice only displayed a 3 fold increase in HDL-C while
human ApoA-I transgenic mice injected with the same dose had a 10 fold
increase.Given that the interaction between LCAT and its cofactor ApoA-I is species
specific, and human LCAT is known to prefer human ApoAI over mouse ApoA-I, we
anticipated that the MED of AAV8-TBG-hLCAT would be lower in LCAT KO/ hApoA-I
transgenic mice than in LCAT KO mice.
After determination of the MED in LCAT KO mice, we wanted to test AAV-hLCAT
in LCAT KO/hApoA-I transgenic mice in order to test the hypothesis that our vector
expressing the human LCAT transgene would be more effective at a lower dose in mice
that express the human apoA-I cofactor for activating LCAT. Because we expected the
MED to be lower in these mice, we tested only the three lower doses (N=5), 1e9 GC,
3e9 GC and 1e10 GC per mouse in this experiment. Again, a control group was injected
with AAV-Null. In these mice, 1e10 GC resulted in large and significant increases in TC
and HDL-C as well as ApoA-I (Figure 6A, B and C). Mice in the high dose group (1e10
GC) had a mean TC of 580±32 mg/dL at 4 weeks post-injection, as compared to
approximately 75±12 mg/dL at baseline. This TC value is well above the normal range
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for these mice, which is 175-225 mg/dL. The HDL-C in these mice ranged from 45±7
mg/dL in null injected controls, which were comparable to baseline, to 392 mg/dL in the
1e10 GC group. Again, this HDL-C is well above the normal range of normal ApoA-I tg
mice, which is 140-160mg/dL. 3e9 GC did not produce any statistically significant
increases in plasma lipids, although the mice in this group did have a significant increase
in their %CE, approaching normal at around 45% (Figure 6D). The high dose group had
a normal %CE around 60% which is considered normal for these mice. We also
analyzed plasma FPLC profiles, the same as done in the previous experiment. Unlike in
LCAT KO mice, LCAT KO/hApoA-I transgenic mice have a bimodal distribution of HDLC which is more similar to a human FPLC profile than the single peak we see in LCAT
KO mice (Figure 6E). In our AAV injected LCAT KO/hApoA-I mice, we see that null
injected mice have an abnormal HDL-C peak which is singular and large in size, at
fraction 28, while the 3e9 GC injected mice have a more normal human-like bimodal
distribution, albeit with less cholesterol (i.e. fewer particles) than the mice that received
1e10 GC. The high dose mice have much higher HDL-C peaks, which skew towards a
larger size, indicating more mature HDLs. From this experiment, we conclude that the
MED of AAV-hLCAT in LCAT KO/hApoAI mice is 3e9 GC per mouse, which is
approximately equivalent to 1.5e11 GC per kg. This is a half log below the MED in LCAT
KO mice.
To ensure that our dilutions and dosing were consistent between the two
experiments, we measured plasma LCAT mass in the mice from this experiments as
well as the second experiment in LCAT KO mice, shown in Figure 4. Comparing plasma
LCAT mass across these two experiments reveals that LCAT mass is dose dependent,
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ranging from 5±2U/L at 3e9 GC, to 73±8 U/L at 1e11 GC per mouse (Figure 7A and 7B).
In the 1e10 GC dose groups in both experiments the concentrations are comparable at
around 14 U/L. This reassures us that dilution of the vector was consistent between the
two experiments.

Identification of a naturally-occurring gain-of-function variant in human LCAT
Given the success of Glybera, which used a naturally occurring gain-of-function
variant of the enzyme LPL, we wished to also take advantage of this particular strategy.
The hLCAT variant V114M is associated with increased HDL-C in the human population
(Table 1)85. We hypothesized that this variant was a gain-of-function variant of LCAT, as
this association suggests. We also predicted that the two hLCAT variants associated
with decreased HDL-C in the human population, which served as negative controls for
our in vitro studies, would have decreased activity in vitro.
First, we tested the in vitro activity of these three variants, and the catalytic serine
mutant negative control, S205G, to determine the effect of these mutations on enzyme
activity. When tested on our exogenous substrate, recombinant HDL, V114M had
increased specific activity relative to WT human LCAT, about 150%, consistent with its
association with increased HDL-C (Figure 8B). Additionally, R123H demonstrates
reduced specific activity relative to WT, at 60±3%, also consistent with its HDL-C
association. Specific activity of S232T was not significantly different from WT. It is
important to note that although we did not measure gene expression in our transfected
cells, that there was a wide range of LCAT concentrations in the media of transfected
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cells, ranging from around 500 ng/mL in the V114M transfections to around 1700 ng/mL
in the R123H transfections (Figure 8A). These differences however, should not affect the
outcome of our next experiment as all activity calculations were normalized to the LCAT
concentration. Next, in order to better understand the properties of V114M, potentially a
gain-of-function variant, we also tested the specific activity of WT human LCAT and
LCAT-V114M on a range of substrate concentrations (Figure 8C). Using a fit to the
Michaelis-Menten equation, we calculated the Vmax and Km constants for both enzymes.
While WT LCAT has a Vmax of 22.56 (95% CI 20.3-25.0) on our substrate, LCATV114M had a Vmax of 37.03 (95% CI 34.4-39.8) (Table 2). The Km of the two enzymes
were comparable, at 0.3 (95% CI 0.22-0.39) and 0.38 (95% CI .31-0.44) . Overall, these
data suggest that V114M is in fact a gain-of-function variant of LCAT having higher
activity than WT and that V114M does not affect lipid or substrate binding, but somehow
affects efficiency of the active site.

Testing AAV8-TBG-hLCAT-V114M in vivo: determination of the MED
After confirming that hLCAT-V114M had increased activity in vitro relative to WT,
we wished to test this variant in vivo to determine the MED of this new vector. We
hypothesized that this variant, hLCAT-V114M would reduce the MED of AAV-hLCAT
and that the MED of AAV-hLCAT-V114M would be lower than the MED of AAV-hLCATWT in both LCAT KO and LCAT KO/hApoA-I transgenic mice. For these experiments,
because we are so interested in this variant as a therapeutic, we will express certain
data as % of human, such that we can better understand how these values may apply to
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the clinical situation.
Here, we aimed to confirm that hLCAT-V114M is indeed a gain-of-function
variant in vivo and to determine if hLCAT-V114M will lower the MED of our vector. To
test this, we injected LCAT KO mice (N=7) with one of three doses of AAV expressing
WT human LCAT (AAV-hLCAT-WT), human LCAT-V114M (AAV-hLCAT-V114M), or a
Null control vector (AAV-Null). We chose to use three low doses in this experiment,
based on our previous experiments and our hypothesis that V114M will lower the MED :
3e8 GC, 1e9 GC and 3e9GC per mouse. Additionally, we harvested livers from these
mice 6 week post-injection to determine if WT LCAT and LCAT-V114M are expressed
equally.
As before, we measured plasma lipids in injected mice. The mice in the high
dose AAV-V114M group has significantly higher TC and HDL-C than mice in all of the
other groups at 82±7 mg/dL and 59±4 mg/dL respectively, however, mice that received
3e9 GC of AAV-WT did not have significantly increased plasma TC, but did have
significantly increased HDL-C, at 20±3 mg/dL, relative to AAV-Null, 8±2 mg/dL (Figure 9
A and B). If we compare the high dose hLCAT groups, AAV-hLCAT-V114M had
dramatically higher plasma TC, at 82±7 mg/dL as compared to 46±3 mg/dl in the WT
group, and HDL-C, at 59±4 compared to 20±3 mg/dL in the WT group. When we
fractionated pooled plasma samples by FPLC, we see that mice in the high dose V114M
group had more cholesterol in large HDL particles, fractions 30-36, than mice in the WT
group, consistent with increased LCAT activity and more mature HDL particles.
Mice injected with AAV-hLCAT-V114M also had higher plasma %CE than WT
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injected mice at both 1e9GC and 3e9 GC (Figure 10A). The MED of AAV-hLCAT-WT in
this experiment was 3e9 GC per mouse, a half log below what we concluded in our first
experiments in LCAT KO mice, and the same as the MED we observed in our previous
experiment with LCAT KO/hApoAI mice. Mice injected with 3e9 of AAV-hLCAT-V114M
had significantly higher plasma CER, about 60% of human plasma activity, than mice
that received the same dose of AAV-WT, about 20% (Figure 10B). WT and V114M were
indeed expressed equally as measured by both RT-PCR and by ELISA for plasma LCAT
mass (Figure 10C and 10D). Despite having similar plasma LCAT concentrations, the
MED of AAV-hLCAT-V114M based on these data, is 1e9 GC per mouse, a half log
below the MED of its WT counterpart.
Since we showed that V114M has higher activity in vivo, we believe that this
naturally occurring variant may be a good candidate for use in a clinical AAV vector for
the treatment of FLD. So, in order to better predict what the therapeutic dose of AAVV114M might be in human FLD, we again tested our AAVs in LCAT KO/hApoA-I
transgenic mice. We tested a single dose in LCAT KO/hApo-I mice, 3e9 GC per mouse.
Mice in the V114M group had significantly higher total TC and HDL-C compared to WT,
at 208±15 mg/dL of TC in the V114M group at 6 weeks post injection and only 80±7
mg/dL in the WT group (Figure 11A). HDL-C in AAV-hLCAT-V114M injected mice was
165±22 mg/dL, while WT injected mice remained at baseline at 57±6 mg/dL (Figure
11B). The WT group in this experiment did not have any significant increases in plasma
lipids relative to AAV-Null control injected mice. Plasma cholesterol FPLC profiles in
injected mice demonstrate the expected human-like bimodal distribution of HDL
particles, with V114M injected mice having much more HDL-C overall, but particularly in
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larger, more mature HDL particles, fractions 28-35 (Figure 11C).
Unlike our experiment in LCAT KO mice, both LCAT injected groups had
approximately 60% plasma CE , approaching a normal ratio, at 60% (Figure 12A).
Animals in the AAV- V114M group had significantly higher plasma CER, at about 80% of
human, while the WT group had only 40% which was not significantly different from the
AAV-Null injected group (Figure 12B). Plasma LCAT concentration did not differ
between the WT and V114M groups (Figure 12C). Similar to our previous experiments,
WT hLCAT and LCAT-V114M were expressed equally in these mice expression was
comparable for both constructs (Figure 12D). The mean plasma LCAT mass in this
experiment was comparable to the previous experiment as well, at around 80% of the
normal human concentration. Because we only tested a single dose in this experiment,
we do not have enough data to determine the MED of AAV-hLCAT-V114M in these
mice. However, based on the data in LCAT KO mice, and the previous studies of AAVhLCAT-WT in both LCAT KO and LCAT KO/hApoAI mice, we can estimate that the MED
in these mice is at or below 1e9 GC per mouse, approximately equivalent to 5e10 GC
per kg of bodyweight.

Examining the effect of hLCAT-V114M on FLD patient plasma lipid profiles
hLCAT-V114M has higher activity than WT hLCAT as we demonstrated both in
vitro and in vivo. hLCAT-V114M lowered the MED of our AAV8-TBG vector in both LCAT
KO and LCAT KO/hApoA-I transgenic mice. At this point in our studies, were were
confident that hLCAT-V114M would be our clinical candidate. However, without a mouse
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model that accurately recapitulates important aspects of the human FLD phenotype,
such as LpX and renal disease, we had no way of testing the efficacy of hLCAT-V114M
on clinical parameters. Therefore, we chose to test the ability of hLCAT-V114M
expressed in cell media, to normalize the plasma lipid profile of two FLD patients.
We hypothesized that at the same concentration, hLCAT-V114M will have a
greater normalizing effect in FLD plasma than WT hLCAT, producing greater reductions
in LpX. We examined the ability of this variant to normalize the plasma FPLC
cholesterol profiles of two FLD patients. First, we measured CER in the plasma of two
FLD patients, in order to confirm the absence of activity (Figure 13A). Consistent with
the FLD diagnosis, the plasma CER from both patients did not differ significantly from
background levels,. We measured a variety of plasma lipids in both patients and a
healthy control (Table 3). Both patients have low HDL-C at 1.7 and 13.9 mg/dL, low
ApoA-I concentrations at 46 and 36 mg/dL as well as low %CE at -9.79% and 13.64%,
consistent with LCAT deficiency. To test the effect of LCAT-V114M on the abnormal lipid
profile of FLD patients, particularly the abnormal lipoprotein LpX, we incubated 3H
labeled patient plasma with transfection media collected from transient transfection of
HEK293 cells. LCAT concentration in each sample was measured by ELISA and then
samples were diluted to match the concentrations before incubation, excluding GFP.
After a 15 hour incubation, the plasma sample that was incubated with WT LCAT had
total %CE at 8±1% as compared to GFP background at 2.5% (Figure 9B). However, the
plasma sample incubated with media containing hLCAT-V114M had total %CE of 12±3%
(p=0.0037 compared to WT), a difference that is consistent with data from our previous
in vitro assays. We fractionated these incubated samples by FPLC and using scintillation
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counting we can see that there is a reduction in the amount of total cholesterol contained
in the LpX peak in the sample that was incubated with hLCAT-V114M, fractions 8-13. In
addition, we see the appearance of LDL, fractions 20-25, and HDL, fractions 37-41, in
this patient sample (Figure 13C). In comparison, there is no decrease in the amount of
cholesterol in the LpX peak, in the WT sample, and no visible HDL. However, WT LCAT
did produce some LDL in this patient sample. When we examine the breakdown of FC
and CE in each of these peaks, we see that while the LpX (VLDL) peak in the GFP
incubated sample has under 5% CE, the same peak in the V114M sample contains over
10% CE (Figure 13D, 13E and 13F). Percent CE in the WT LpX peak remains similar to
baseline, although there appears to be small increases in the %CE in both the LDL and
HDL peaks in the WT sample. Overall, these data suggest that hLCAT-V114M is more
effective at reducing LpX, thereby normalizing the FLD plasma lipid profile, than WT
hLCAT.
Investigating the mechanism of gain-of-function of hLCAT-V114M
To examine the gain-of-function mechanism from an un-biased view, we created
and tested the in vitro activity of 18 additional LCAT variants, each with one of the
remaining amino acids at position 114. Specific activity of these variants ranged from
10% to 220% of WT (Figure 14A). When we examine the relationship between the size
of the amino acid (using molecular weight as a surrogate) and the activity of each
variant, we see that there is a positive correlation, with an r2 value of 0.5878. We can
see that there is one amino acid that is an outlier. This amino acid is tryptophan. If we
exclude tryptophan from the analysis, we get a correlation of 0.9771, which is a very
strong relationship (Figure 14C). In contrast, if we plot the relationship between the
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hydrophobicity index of each amino acid and the activity of its associated variant, we see
no correlation (Figure 14D).
To gain more insight regarding the possible mechanism of gain-of-function of
LCAT-V114M, we chose to model this variant using molecular dynamics simulation. As
we do not currently have a method of capturing protein structure over time in a biological
system, an alternative approach is molecular dynamics simulation (MDS), which like
other in silico methods, combines the principles of physics and chemistry with computer
technology to predict the outcome of a given set of inputs and parameters. In the case of
MDS, the input in a three dimensional structure, typically a representation of a protein
derived from X-ray crystallography. The parameters are a set of physical principles
which govern the movement of the atoms that make up the protein.
Three dimensional structures of WT LCAT and LCAT-V114M were generated
based on the recently published crystal structure 21, and their behavior in a solventexposed (aqueous) environment was simulated over a period of 10ns (Figure 15A). Both
structures achieved stability during this time period, as measured by root-mean-squaredeviation (RMSD) (Figure 15B). To examine local structural fluctuations over the course
of the simulation, we plotted the root-mean-square-fluctuation (RMSF) values for each
protein across the length of the amino acid sequence (Figure 15C). Comparing two
plots, there are several regions of the LCAT protein where V114M is to predicted to alter
local structural movement, one of these regions, residues 220-250, stands out as the
region with the highest RMSF value, is the lid loop.
Figure 16A shows the position Valine 114 within the LCAT protein structure.
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Valine 114 is positioned in the membrane associating region of LCAT, near the junction
of the three domains. In Figure 16B, you can see the position of the lid loop which is the
structure that partially blocks access to the active site. We consider this region of several
regions of interest based on these simulations. These regions of interest are residues
45-75, 125-175, 220-250, 290-310 and 320-340 (Figure 16C). Residues 45-75 fall in the
membrane-associating domain. Residues 125-175 are located in the hydrolase domain,
290-310 and 320-340 are in the cap domain. Importantly, none of these regions contain
any of residues that form the substrate-binding pocket, any of the catalytic triad or make
up any other previous identified relevant structures. However, residues 220-250 make
up the lid loop, a flexible loop which blocks access to the active site and is known to be
important in enzyme activation and regulation 106,107. It is difficult to discern which of
these regions may be of the greatest importance based on this simulation alone. We
chose to simulate a selected number of our 114 variants, chosen based on their specific
activity. We chose to model V114G and V114P because these variants have relatively
low activity. We also chose to model V114I because of its similarity to V11M, both in
structure and activity, and V114Y because of its striking increase in specific activity.
When we compare the delta-RMSF profiles of these 4 new variants to LCAT-V114M
(Figure 16D), in five regions of interest, V114M stands out in that it is the only variant
predicted to increase flexibility (delta-RMSF) across the entire lid loop.
Testing codon optimized variants of hLCAT
Li and Sharp first showed that there is an evolutionary codon usage bias that
correlates with gene expression: highly expressed genes are under selective pressure to
use the codon corresponding to the anticodon of the most abundant tRNA for a given
39

amino acid (which differs between organisms, and even between tissues)108. Since then
additional constraints on codon selection have reveal biases beyond simple frequency,
including co-occurrence, and pair bias 109 Codon optimized sequences have been used
to improve transgene expression in several preclinical studies of gene therapy 91,92.
However, in almost all cases, only a single variant was tested and in many cases this
variant was not directly compared with the WT sequence. Because the factors that
contribute to differences in codon translation efficiency are multivariate and complex, it it
unlikely that a single optimization algorithm will reliably predict the best expressed
sequence. Therefore, we chose to compare four codon optimized variants of human
LCAT, side by side, to determine the best candidate.
We hypothesized that one or more codon optimized hLCAT variants will be more
effective than hLCAT-WT when expressed in vivo, inducing greater increases in plasma
lipids than AAV-hLCAT-WT. Following the in silico analysis of the many potential codon
optimized LCAT variants, we selected four candidates (variants 1, 11, 26 and 201) to
test in vivo. Each variant was synthesized and then cloned into a plasmid for AAV
production. For our pilot experiment we selected C57BL/6J mice and two doses, 1e10
GC per mouse and 1e11 GC per mouse (N=4), with AAV-Null and AAV-hLCAT-WT
injected mice served as controls. We measured plasma lipids in these mice before
injections and every 2 weeks after, as per our standard lab protocol. 6 weeks postinjection, none of the low dose groups had any significant differences in their plasma
lipids relative to null injected mice (data not shown). The high dose hLCAT groups
however, all had significantly increased TC and HDL-C relative to controls, with variant 1
(AAV-hLCAT-v1) having the highest TC at 201±6 mg/dL, and HDL-C at 152±3 mg/dL),
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followed by the AAV- hLCAT-v11, and hLCAT-WT groups (Figure 17A and 17B).
Although the AAV-hLCAT-v1 group had the highest lipids, this was not statistically
significantly different from any of the other AAV-hLCAT groups. With respect to plasma
%CE, four of the five AAV-hLCAT groups had significantly elevated %CE relative to null,
only AAV-hLCAT-v201 was not significant (Figure 17C). This first test of the codon
optimized variants may not have been very sensitive, as it was performed in an
overexpression setting, where small differences may be masked by normal baseline
concentrations of LCAT. Therefore, we decided to test these variants again, this time in
LCAT KO mice.
Results in LCAT KO mice were similar to the results in C57BL/6. This time we
injected only a single dose of each vector (N=7), 1e10 GC, and added AAV-hLCATV114M as a positive control comparison. When we measured plasma lipids in these
mice, we found that the AAV-hLCAT-V114M had by far the highest TC, at 140±7 mg/dL
and HDL-C, at 100±4 mg/dL, with AAV-hLCAT-v1 being the second highest, although
statistically comparable to AAV-hLCAT-WT at approximately 75mg/dL of TC and 50 mg/dL of
HDL-C (Figure 18A and 18B). Non-HDL-C was not different between any groups in this
experiment, despite the increase in TC in the AAV-hLCAT-V114M group (Figure 18C).
Plasma %CE was in the normal range for all AAV-hLCAT injected groups, ranging from 6379% (Figure 18D).
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Discussion
The MED in LCAT KO mice: 1e10 GC of AAV-hLCAT increases plasma %CE
Although our first in vivo test of AAV-hLCAT did not produce any statistically
significant responses, we can see that at a dose of 1e10 GC there is some response to
the vector and that this response is stable for a relatively long period of time, out to 12
weeks post injection (the longest post-injection timepoint sampled). At the time that we
conducted the first experiment, based on the lack of significant changes in plasma lipids
we did not measure %CE in these mice. Our subsequent experience indicates that it is
typical to see a significant increase in %CE before seeing an increase in plasma lipids,
(as demonstrated in our second experiment). Because of the lack of a significant
plasma lipid response in this first experiment, we subsequently repeated the high dose
and also tested two higher doses, 3e10 and e11 GC per mouse. Here, we saw that both
of the two high doses induced a significant response in mice as measured by plasma
lipids, CER, and LCAT mass. However, the same dose, 1e10 GC per mouse, that
produced no significant increase in plasma lipids, did in fact induce a significant increase
in plasma %CE, in this case to a normal level at ~70%. From these two experiments we
can conclude that the MED of AAV-hLCAT to be at or below 1e10 GC per mouse. In
later experiments, we tested several lower doses of AAV-hLCAT in LCAT KO mice and
we found that at a dose of 3e9GC per mouse, there was a significant increase in
plasma %CE in this group. We would likely have seen the same result had we measured
%CE in our initial experiment (Figure 2). These data together lead us to conclude that
the tested MED of this vector in LCAT KO mice is 3e9 GC per mouse, which is
approximately 1.5e11 GC per kg.
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hApoA-I lowers the MED: 3e9 GC of AAV-hLCAT increases plasma %CE
When we initially tested our AAV-hLCAT vector in LCAT KO/hApoA-I transgenic
mice, we determined the MED (3e9GC) to be a half log lower than the MED in LCAT KO
mice (1e10 GC). However, if we view all of our data together, including data from later
experiments (Figures 10 and 12) we can conclude that the MED in LCAT KO mice is
indeed also 3e9 GC per mouse. While this seems to suggest that the presence of
human ApoA-I does not decrease the MED of our vector, data from later experiments
suggests thats not the case. There may be an explanation for this discrepancy. In later
experiments we used a newer lot of AAV-hLCAT, produced in 2015 and larger numbers
of mice, making it more likely to see a significant response at a lower dose. This is in
contrast to the older lot of vector we used in our first experiments (Figures 4, 5,6 and 7),
which was produced in 2006. Although overall the results are comparable between the
two lots, the older lot does seem to be slightly less potent, which could be the result of its
age or the difference in the titering method.
In any case, in earlier experiments, a dose that produced only a small and not
significant increase in plasma lipids in LCAT KO mice (1e10 GC, Figures 4 and 5)
produced much more dramatic and statistically significant increases in LCAT KO/hApoAI mice (1e10 GC, Figure 6). Also, while 3e9 GC had no effect on plasma lipids in LCAT
KO mice, we did see a small but not significant effect in LCAT KO/hApoA-I mice, similar
to the effect of 1e10 GC in LCAT KO mice. In our later experiments, we consistently see
that a dose of 3e9 GC per mouse induces small increases in both TC and HDL-C
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(whether statistically significant or not) and produces a statistically significant increase in
the plasma %CE in both LCAT KO and LCAT KO/hApoA-I mice. Altogether, this
suggests to us that there may be an effect of the human cofactor, but the difference in
the MED is likely less than half a log. This would explain why sometimes we see a dose
difference between the two strains, and sometimes we do not.

Human genetic associations predict the in vitro activity of LCAT variants
In vitro, V114M, has ~150% the activity of WT LCAT, consistent with its human
lipid association (Figure 6). This makes V114M the first gain-of-function variant of LCAT
ever described. Not only did V114M have increased activity in vitro, but this difference is
robust across LCAT KO and LCAT KO/hApoAI transgenic mice, as well as in human
plasma (Figures 9-13). We also showed that V114M is not the only LCAT variant to have
activity consistent with its human lipid association. R123H is associated with decreased
HDL-C in the human population and also demonstrated reduced activity, ~60% of WT,
when tested in vitro. We did not pursue any additional testing of this variant, but we
expect the difference in specific activity to remain consistent across other models, similar
to V114M. These data demonstrate the power of human genetic studies to identify
functionally relevant sequence variants, including high activity variants which may be
especially therapeutically relevant.
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The MED of AAV-hLCAT-V114M: 1e9 GC of AAV-hLCAT-V114M increases %CE
We already demonstrated that hLCAT is reliably expressed via liver transduction
using AAV2/8 and induces dose dependent increases in plasma lipids in both LCAT KO
and LCAT KO/hApoA-I mice. Now we have identified a gain-of-function variant of human
LCAT that may be ideal for use in our clinical candidate vector. The use of this naturally
occurring gain-of-function variant, analogous to the strategy employed by the developers
of Glybera, will likely lower the MED of our vector. When we tested the in vivo response
to AAV-hLCAT-V114M, we found that a significant increase in plasma %CE, can be
seen in LCAT KO mice at a dose as low as 1e9GC per mouse (approximately equivalent
to 5e10 GC per kg). In these studies, the low dose of 3e9 GC/mouse (~1.5e11 GC/kg)
normalized plasma %CE in LCAT KO mice and at this dose, V114M produced plasma
lipids near normal levels. In LCAT KO/hApoA-I transgenic mice, both hLCAT vectors
produced normal plasma %CE, but only V114M produced significant increases in
plasma lipids and CER. Given that we only tested a single dose in LCAT KO/hApoA-I
mice, it is possible that an even lower dose of AAV-V114M may produce significant
increases in plasma %CE in these mice. From these studies, we conclude that the MED
of AAV-hLCAT-V114M is 1e9 GC per mouse (5e10 GC per kg). This dose is nearly ten
fold lower than the approved dose used for Glybera 77, 1e12GC per kg, and more than
10 fold lower than the lowest dose used in a phase I/II clinical trial for AAV gene therapy
for hemophilia B, 2e12 GC per kg 68. Lastly, this estimate of therapeutic dose is based
on changes in plasma %CE. We believe that an improvement in %CE is likely to be
therapeutic, but the dose required to prevent renal failure may be quite different.
Determination of the true therapeutic dose is difficult to impossible to determine without
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a reliable animal model of FLD renal failure and without testing in human patients.
However, this dose gives us a starting point.

hLCAT-V114M is better at normalizing FLD patient plasma than hLCAT WT
At the time of this study, because we lacked an appropriate animal model to test
the efficacy of gene therapy to prevent renal disease in FLD, we chose to test our gainof-function LCAT in plasma from two FLD patients. When incubated with patient plasma,
LCAT V114M reduced LpX-C and increased LDL-C and HDL-C, while WT hLCAT failed
to reduce LpX and only increased LDL-C. The total cholesterol esterified by V114M
during the incubation was nearly double that of WT LCAT, 5% in WT compared to 9.5%
in V114M. We would expect similar results in a human patient, with V114M being twice
as effective at reducing LpX cholesterol. Given the data demonstrating that LpX is
sufficient to induce renal dysfunction in LCAT KO mice 54, we would expect V114M to be
a more effective at preventing renal failure in FLD than WT LCAT. This is consistent with
all of our previous data and supports the idea that V114M will be a better choice for our
candidate vector.

Molecular dynamics simulation suggests V114M increases flexibility of the lid loop
X-ray crystallography is the gold standard method of determining the structure of
a protein. However, the determination of protein structure while immobilized in nonphysiologic conditions merely provides an average or just a single version of the protein
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structure. In solution, the physical organization of a protein may be quite different from
that represented by X-ray crystallography and this is important to keep in mind when
examining the relationship between protein sequence, structure and function. While
crystal structures are stationary, in a true biological system, a protein is more fluid
structure with various flexible, and sometimes moving, parts. Molecular dynamics
simulation attempts to fill this gap in knowledge, by combining our knowledge of protein
structure, with computer modeling to form predictions of protein structure that take into
account the effects of the aqueous environment.
Understanding the mechanism of gain-of-function can be useful for a variety of
reasons. Firstly, one may be able to exploit this mechanism to engineer high activity
variants of other enzymes, in this case, particularly lipases. Also, if a protein is to be
used therapeutically, understanding the mechanism contributes to the knowledge base
and potentially to the safety profile of the therapeutic product. Here we show that
molecular dynamic simulation suggests V114M increases flexibility of the lid loop. In
lipases, opening of the lid loop is essential for activation of the enzyme, providing the
substrate access to the active site, and is facilitated by conformational changes that
occur upon membrane association 110. For these reasons, the lid loop is known to be an
important determinant of enzyme activity 111. It is therefore reasonable to assume that
increased flexibility of the active site lid loop may reduce the activation energy of the
enzymatic reaction thereby increasing the specific activity. In fact, this conclusion is
consistent with the results of our kinetic study (Figure 8 and Table 2), where we see an
increase in the Vmax of LCAT-V114M but no change in the Km. Given the location of
V114, at the junction of the three domains, opposite the active site, and given that larger
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amino acids at this positions predict increased activity, we believe that V114M induces
slight conformational changes via interaction with the neighboring domains, which
ultimately leads to changes in the function of the lid loop. However, we cannot rule out
additional mechanisms by which V114M increases the activity of LCAT. There may be
other reasons for this gain-of-function that we cannot discern from these studies alone.

Side by side comparison of four codon optimized variants of hLCAT
We designed and tested four codon optimized variants of LCAT. Only one of the
four variants, variant 1, appeared to be better than WT hLCAT at increasing plasma
lipids in mice. We have not yet confirmed if this variant is expressed more efficiently, as
we would predict based on the theory of codon optimization and based on previous
studies. The remaining three variants appear to be equivalent to or less effective than
WT at increasing plasma lipids in both BL6 and LCAT KO mice. As none of the groups of
mice injected with an AAV expressing one of the codon optimized variants were
significantly different from mice injected with AAV expressing the WT hLCAT, these
studies suggest that the LCAT gene is not strongly affected by codon optimization. This
work is ongoing. In the near future we will examine expression of the different variants
by RT-PCR and LCAT ELISA. We also intend to combine variant 1 with our gain-offunction LCAT, hLCAT-V114M, as we anticipate me might see a more dramatic effect.
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Conclusions
Here we have identified the first naturally occurring gain of function variant of
LCAT and determined the MED of a vector expressing this variant. The MED, defined as
the lowest dose which produces significant increases in plasma %CE, of this vector, our
current clinical candidate, is approximately 5e10 GC per kg of bodyweight. In addition to
the identification and characterization of this naturally occurring gain-of-function variant,
here, we directly compared four different codon optimized variants of hLCAT. While
none of the codon-optimized variants were significantly better than WT hLCAT, our data
suggests that v1 might be slightly more effective. This effect, while seemingly small, may
have a combinatorial benefit with our gain-of-function variant, and ultimately produce a
vector that is even more effective. Currently, we are in the process of combining these
two findings into a single maximally effective vector for testing in a clinical trial.
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Materials and Methods
In vivo AAV Expression in Mice
WT LCAT and LCAT-V114M were cloned into AAV plasmids containing the
human TBG promoter and alpha mic/bik enhancer, as used in previous studies
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Plasmids were then submitted to the Penn Vector core for production of our
pseudotyped (serotype 8) AAV2 vectors (AAV2/8). LCAT KO mice 101 and LCAT
KO/human ApoA-I transgenic mice 113 are maintained in our animal facility on standard
chow diet. 6-10 week old male mice received a single intraperitoneal injection of vector
diluted in sterile PBS. Blood samples were collected prior to injection and every 2 weeks
thereafter via retro-orbital bleed. Animals were sacrificed for tissue collection 6 weeks
after AAV injection. Livers were collected immediately following perfusion with sterile
PBS. Plasma lipids were measured using an AXCEL autoanalyzer. The following
reagents were used: for Total Cholesterol, Wako TC reagent (catalog# 439-17501), for
Free Cholesterol, Wako FC reagent (catalog# 435-35801), for HDL-C, Trinity EX HDLCholesterol reagent (Trinity catalog#354 LB) and for Phospholipids, the Wako
Phospholipids C reagent (catalog# 433-36201). FPLC lipid profiles of injected mice were
obtained by the separation of 150ul of pooled plasma using two Superose 6 columns in
series. Lipids were measured in FPLC fractions using the same reagents used for
plasma lipids.
Plasma Cholesterol Esterification Rate (CER) Assay
30μl (30 μCi) of 3H labeled free cholesterol was dried down under nitrogen gas
and then resuspended in 300 μl of ethanol. For each sample to be run, 6μl of the
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resuspended cholesterol solution was spotted onto a filter paper disc in the bottom of a
glass culture tube, for a total of 0.6μCi per reaction. Plasma from AAV injected mice,
stored at -80ºC, was thawed on ice. 8μl of 1.4mM DTNB (5,5-dithio-bis-(2-nitrobenzoic
acid) solution was added to each tube before the addition of 40 μl of plasma. Each
sample was run in triplicate. PBS was used as a negative control, and a pooled human
plasma standard was run as a positive control. Tubes were capped and incubated in a
37ºC shaking water bath for 2 hours for equilibration. After equilibration, 8μl of 0.1M
BME solution was added to each tube and then tubes were recapped and incubated for
another 60 minutes in the shaking 37ºC water bath. Reactions were terminated by the
addition of 2ml of 2:1 chloroform: methanol solution and a brief vortex. 200ul of water
was added to each tube to induce phase separation and then tubes were centrifuged for
5 minutes at 400 x g. The clear bottom layer was carefully moved to a clean glass tube
and then dried down via centrifugal evaporator or nitrogen dryer. Dried samples were
resuspended in 50ul chloroform containing unlabeled FC and CE carrier for thin layer
chromatography (TLC). Labeled FC and CE in each sample was separated by TLC
using 170:30:1 Hexane: Diethyl Ether: Acetic Acid. Spots were cut and quantified using
scintillation counting. FC was measured in each plasma sample using Wako Free
Cholesterol kit. CER for each sample was then calculated as percent of cholesterol
esterified per hour * nmol FC per ml of plasma.
Gene Expression
RNA was isolated from liver tissue via homogenization and extraction with Trizol
(Fisher catalog# 15596018) as described by the manufacturer. Isolated RNA was
washed three times before final resuspension. The concentration of RNA was measured
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by Nanodrop and all samples were diluted to match the concentration of the most dilute
sample in the set. RNA was deemed of sufficient quality at or above a 260/280 ratio of
1.5. RNA samples with a 260/280 ratio below 1.5 were precipitated with isopropanol,
washed and resuspended until the 260/280 ratio reached at least 1.5. cDNA was created
using the Applied Biosystems High Capacity Reverse Transcriptions cDNA Synthesis kit
(Fisher catalog#4368814) following the manufacturer’s protocol. cDNA was diluted 1:50
in RNase free H20 before PCR. PCR reactions were set up in a 384 well optical plate.
Each 10ul reaction contained 5 μl of SYBR Green Master Mix, 3μl of diluted cDNA and
1μl of each primer. After loading all samples, plate was spun briefly in a tabletop
centrifuge before being analyzed using Applied Biosystems QuantStudio 7 Flex Real
Time PCR System. On every plate, a standard curve was created for each primer set
using serial dilutions of pooled cDNA, in order to demonstrate consistent amplification
efficiency and to quantify mRNA if so desired. The following primer sequences were
used. For mouse beta-actin: 5’-TTGGGTATGGAATCCTGTGG-3’ and 5’CTTCTGCATCCTGTCAGCAA-3’. For mouse 18S: 5’-CTTAGAGGGACAAGTGGCG-3’ and 5’ACGCTGAGCCAGTCAGTGTA-3’. For human LCAT: 5’-CCAGGGTTGTCTACAACCGG-3’ and
5'-GGCGCAGCAGGAAATAGAGC-3' .

Cell Culture and In Vitro LCAT Activity Assay
LCAT V114M, R123H, S232T and the catalytic serine mutant S205G were
created using the pcDNA3.1+ expression plasmid containing the WT LCAT cDNA and
the Quik-Change II XL Site Directed Mutagenesis kit from Agilent Technologies
(catalog#200521). All V114 LCAT variants were created using GeneStrand fragments
from Eurofins. Gene fragments were cloned into the same pcDNA3.1+-hLCAT used
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previously. After thawing, HEK293 cells were passaged 2-3 times in standard serum
medium (such as DMEM w/FBS). Cells were then adapted to serum free medium
(Freestyle 293 Expression Medium from ThermoFisher catalog #12338026) by reducing
the volume of serum containing medium each passage. A trypsin inhibitor (ThermoFisher #T6522) was added to media immediately after trypsinizing to prevent death of
the cells. Once adapted, cells were plated at 3x105 cells per well, in 12-well plates for
transient transfection. At approximately 80% confluency, or 24-48 hours later, cells were
transfected using Lipofectamine 2000 (Fisher catalog# 11668019). 4μg of each plasmid
DNA construct was used per well, with each construct repeated in triplicate wells. Media
was changed 6 hours later and then collected 48 hours post-transfection. Media samples
were aliquoted and frozen at -80ºC immediately after collection.
We performed our in vitro LCAT activity assay in a manner similar to that
published by Vaisman et al in 2013114 Recombinant HDL (rHDL) was prepared by
cholate dialysis using POPC (Avanti Lipids #850457), ApoA-I (purified in house from
pooled human plasma) and free cholesterol (Avanti Lipids #250165) at a mass ratio of
2.7:1:0.11 respectively. Additionally, 3H labeled cholesterol was added to the rHDL at a
ratio of 20μCi/mg ApoA-I. Given that ApoA-I is our limiting reagent, we calculated the
amount of other reagents based on the mass of ApoA-I that was to be used in the
preparation. Briefly, appropriate volumes of POPC and cholesterol solutions were dried
down under N2 gas then resuspended in TBS with EDTA, pH 7.4. The volume of TBS
used for resuspension was calculated based on the volume of dialyzed ApoA-I such that
the total volume of the mixture going into dialysis was 4ml/mg of ApoA-I. 30mg/ml
cholate solution (in TBS with EDTA) was added to the suspension (94ul/mg ApoA-I)
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which was vortexed and then incubated at 37ºC for 90 minutes. Dialyzed ApoA-I was
then added to the mixture which was again vortexed and incubated at 37ºC for another
60 minutes. The final mixture was then dialyzed against 6 x 4L of TBS with EDTA, pH
7.4 over 72 hours. After dialysis, the rHDL was combined with an equal volume of 2%
BSA with 10mM BME (in TBS with EDTA) and stored at 4ºC until the assay was
performed (within one week). Additional BME was added to the rHDL before setting up
the reactions. On ice, 60 μl of rHDL mixture, as prepared above, was pipetted into
labeled tubes. Each reaction was run in triplicate. After inverting each media aliquot 5-7
times, 5ul of media was added to each labeled tube containing rHDL. Reactions were
then incubated in a 37ºC water bath for 2 hours. Upon removal from the water bath,
reactions were terminated by the addition of 1ml of cold 100% ethanol and placed on dry
ice. Reactions were then stored at -20ºC overnight. Next, reactions were centrifuged at
15,000xg for 10 minutes to pellet any protein. The supernatant was moved into matching
labeled glass culture tubes and then dried down using a centrifugal evaporator. Dried
samples were resuspended in 50ul chloroform containing unlabeled FC and CE carrier
for thin layer chromatography (TLC). Labeled FC and CE in each sample was separated
by TLC using 170:30:1 Hexane: DEE: Acetic Acid. Spots were cut and quantified using
scintillation counting. LCAT activity for each sample was then calculated as percent of
cholesterol esterified per hour. Background activity as measured in media samples from
GFP transfected cells was subtracted out and then activity of each variant was
normalized to LCAT concentration as measured by polyclonal ELISA (Biovendor
#RD191122200R). Because exact activity values vary between rHDL preps, data is
presented as relative to WT activity (calculated for each assay).
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For kinetic assays, after dialysis, recombinant HDL particles were separated by
fast protein liquid chromatography (FPLC) on a Superdex 200 column and the fractions
corresponding to 7-8nm diameter were pooled and concentrated using an Amicon
Centrifugal Filter Unit (Sigma-Aldrich #Z648027). Concentrated HDL was then diluted
with TBS w/EDTA to match the cholesterol concentration of a standard prep of rHDL..
Substrate was then further diluted to the appropriate concentrations using TBS w/EDTA,
BSA and BME to match our normal running concentrations.
Molecular Dynamics Simulation
Molecular dynamics simulations were performed using Maestro software
(Release 2015-3; Schrodinger). The high-resolution crystal structure of LCAT (4XWG)
was used as the starting structure21. Using the PRIME application, the missing residues
231-237 were replaced and Y31 was mutated back to C to obtain WT LCAT, containing
all residues of the mature LCAT protein, numbered from 21-396. Using this WT LCAT
structure, V114 was mutated to create the additional variants, V1114G, V114I, V114M,
V114P, and V114Y. Starting structures for each variant were refined by restrained
minimization using the following parameters: Force Field = OPLS_2005; solvent = water;
iterates = 2500. All-atom molecular dynamics simulations were then run for 10 ns using
the Desmond application at a temperature of 310.15 K in SPC solvent with 0.15 M NaCl.
Simulations were performed on the National Institutes of Health Biowulf computing
cluster.
FLD Patient Plasma Incubation with Transfection Media
Fasting plasma was obtained from two FLD patients, shipped overnight on ice
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and then aliquoted and frozen at -80ºC. Thawed aliquots were then used to measure
plasma lipids using our clinical autoanalyzer and reagents as outlined above. LCAT
Activity (CER) was measured using our radiolabeled whole plasma activity assay, using
the protocol identical to what was used in mouse studies. Human LCAT concentration
was measured in media samples collected from transfected HEK293 cells using
polyclonal ELISA (Biovendor #RD191122200R). Media samples were concentrated
using Millipore Amicon Ultra 4 centrifugal units and the ELISA was repeated.
Concentrated media samples were diluted to a final LCAT concentration of 17 mg/ml.
45 μl of medium was mixed with 135 μl of 3H-free cholesterol labeled patient plasma
which was labeled overnight at 4ºC. GFP transfection media was used as a negative
control. After pipetting up and down 5-6 times, samples were incubated in a 37ºC water
bath for 15 hours. Incubation was terminated by placing the samples on ice and then
freezing at 20ºC. A portion of the incubation mixture was separated on a TLC plate to
calculate %CE via scintillation counting. 150μl of the sample was separated by FPLC as
outlined above and then cholesterol distribution was determined using scintillation
counting. To determine the breakdown of FC and CE in each peak, FPLC fractions
across each peak were pooled, dried down and then separated by TLC and again
quantified using scintillation counting.

Design of Codon Optimized LCAT Variants
In collaboration with the lab of James Wilson, we used codon frequency tables
developed in house in earlier studies for expressing various genes in liver to diversify the
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coding sequences for the LCAT protein. Alternative reading frames were removed from
each coding sequence. The diversification was based on the inherent codon degeneracy
and resulted in overall coding sequence variance presented in the Table below. hLCAT
corresponds to the endogenous human gene. Each coding sequence was synthesized
de novo and cloned into AAV cis plasmid under the control of liver specific TBG
promoter. The transgene cassette is flanked by the AAV2 ITR allowing us to package
those transgene expression cassettes into AAV vectors. Those plasmids were verified
by end-to- end sequencing prior to packaging. All vectors were produced by Penn Vector
Core.
Statistical Analyses
All statistical analysis was performed using GraphPad Prism 7.0. One way
ANOVA with Tukey’s multiple comparison test was used to compare groups of a single
level. Two way ANOVA was used when comparing groups with multiple levels, such as
time course data. Student t-test was used to compare pairs or triplets of single time point
data. All in vitro experiments were repeated three times, using independent biological
samples. In vivo experiments used a minimum of three animals per group. Animals were
excluded from analysis if data was missing from one or more timepoints or if the animal
was presumed to have a bad injection. An animal was presumed to have a bad injection
if: at least two plasma lipid measures were more than two standard deviations below the
mean of the other animals in that group AND the plasma LCAT mass or plasma CER
was also two standard deviations below the mean of the other animals in that group.
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Figure 3. 1e10 GC of AAV8-TBG-hLCAT increases Total Cholesterol and HDL-cholesterol
in LCAT KO mice. LCAT KO mice (N=4) were injected with one of three doses of AAV-

hLCAT or AAV-Null. Plasma lipids were measured over a period of 12 weeks. Mice that
were injected with 1e10 GC of AAV-hLCAT demonstrated an increase in plasma TC (A)
and HDL-C (B) although it was not statistically significant as compared to AAV-Null
injected mice. Error bars indicate standard error.
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Figure 4. 3e10 GC of AAV8-TBG-hLCAT significantly increases plasma lipids in
LCAT KO mice. We tested three more doses of AAV-hLCAT in LCAT KO mice (N=5)
and measured plasma lipids out to 6 weeks post injection. Mice injected with 3e11 GC
per mouse and 1e11 GC per mouse of AAV-hLCAT had significant increases in plasma
total cholesterol (A), HDL-cholesterol (B) and phospholipids (C). No differences were
seen in alanine aminotransferase (ALT) (D). * indicates p<0.05, ** indicates p<0.005, ***
indicates p<0.0005 and **** indicates p<0.00005 relative to AAV-Null injected mice.
Errors bars indicate standard error.
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Figure 5. 1e10 GC of AAV8-TBG-hLCAT normalized plasma %CE in LCAT KO mice.
All AAV-hLCAT injected mice had significantly elevated plasma %CE (A). We also
measured total plasma cholesterol esterification rate (CER) in these mice (B) and
measured total cholesterol in FPLC fractions of pooled plasma samples from each group
(C).* indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates
p<0.00005 relative to AAV-Null injected mice. Errors bars indicate standard error.
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Figure 6. 3e9 GC of AAV8-TBG-hLCAT significantly increases plasma %CE in
LCAT KO/hApoAI mice. We injected LCAT KO/hApoAI transgenic mice with one of
three doses of AAV-hLCAT or AAV-Null and measured plasma lipids out to 6 weeks post
injection. Mice that were injected with 1e10 GC per mouse of AAV-hLCAT had
significantly increased plasma total cholesterol (A), HDL-cholesterol (B) and hApoAI (C).
We also measured plasma %CE in these mice (D) and measured total cholesterol in
FPLC fractions of pooled plasma samples from each group (E).* indicates p<0.05, **
indicates p<0.005, *** indicates p<0.0005 and **** indicates p<0.00005 relative to AAVNull injected mice. Errors bars indicate standard error.
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Figure 7. Plasma LCAT mass is dose dependent and comparable between experiments.
We measured plasma LCAT mass in AAV injected mice, 6 weeks after injection by
monoclonal ELISA. Shown in (A) are the plasma LCAT concentrations in injected LCAT
KO mice, in (B) are the concentrations in LCAT KO/hApoAI transgenic mice and shown
in (C) is a comparison of the average plasma LCAT concentration from the two separate
experiments, demonstrating that the concentration is comparable at the same dose. *
indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates
p<0.00005 relative to AAV-Null injected mice. Errors bars indicate standard error.
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Table 1: Naturally-occurring missense LCAT variants associated in heterozygous
state with significantly different HDL-C levels. Shown here is a summary of the three
naturally occurring variants of LCAT identified in the human population at measurable
levels.
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Figure 8. In vitro activity of three naturally occurring variants of LCAT is
consistent with human lipid associations. (A) Concentration of the LCAT variants in
culture medium 48 hours after transient transfection of 293 cells (n=6). (B) In vitro
activity of WT hLCAT and hLCAT-V114M measured on 3H labeled recombinant HDL
(N=3). (C) In vitro activity of WT-LCAT and LCAT-V114M measured on a range of
substrate concentrations Line represents best fit to Michaelis Menten equation. *
indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates
p<0.00005 relative to WT. Errors bars indicate standard error.
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Table 2: Kinetic study suggests V114M increases Vmax of LCAT

65

Figure 9. 3e9 GC of AAV8-TBG-hLCAT-V114M significantly increases plasma
lipids in LCAT KO mice, while AAV8-TBG-hLCAT-WT does not. We injected groups
of LCAT KO mice (N=7) with one of three doses of AAV, 3e8 GC, 1e9 GC or 3e9 GC per
mouse. Mice received either AAV-hLCAT-WT, AAV-hLCAT-V114M or AAV-Null. We
measured plasma lipids, including total cholesterol (A) and HDL-cholesterol (B) before
and every 2 weeks after injection, until the animals were euthanized 6 weeks later. Mice
that received 3e9 GC of AAV-hLCAT-V114M had significantly elevated TC and HDL-C.
We also measured plasma %CE in these mice (C) and measured total cholesterol in
FPLC fractions of pooled plasma samples from each group. HDL peak is at fraction 39. *
indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates
p<0.00005 relative to AAV-Null injected mice. ++ indicate significance relative to AAVhLCAT-WT injected mice. Errors bars indicate standard error.
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Figure 10. 3e9 GC of AAV8-TBG-hLCAT-V114M significantly increases plasma %CE and
CER while AAV8-TBG-hLCAT WT does not. Plasma percent cholesterol ester in injected mice

calculated from plasma lipids measured 6 weeks after injection (A). We also measured whole
plasma cholesterol esterification rate (CER) in AAV-injected mice at this same time point and
expressed it here as percentage of normal human whole plasma CER (B). Plasma hLCAT
concentrations 6 weeks after injection as measured by polyclonal ELISA also expressed as % of
normal human plasma concentration. (C).Lastly we examined gene expression, here we show
human LCAT delta CT values for AAV injected mice (N=7), normalized to mouse beta-actin and
18S (D).* indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates
p<0.00005 relative to AAV-Null injected mice. Errors bars indicate standard error.
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Figure 11. 3e9 GC of AAV8-TBG-hLCAT-V114M induces large increases in total
cholesterol and HDL cholesterol in LCAT KO/hApoAI transgenic mice. We injected
groups of LCAT KO/hApoAI transgenic mice with 3e9 GC of AAV-hLCAT -WT, AAVhLCAT-V114M or control AAV-Null and measured plasma lipids before and after
injection. Animals injected with AAV-hLCAT-V114M had substantial increases in total
cholesterol (A) and HDL-cholesterol (B).We also measured plasma %CE in these mice
(C) and measured total cholesterol in FPLC fractions of pooled plasma samples from
each group. In AAV-hLCAT injected mice, we see a shift towards a human-like bimodal
HDL-C distribution. indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and
**** indicates p<0.00005 relative to AAV-Null injected mice. Errors bars indicate standard
error.
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Figure 12. 3e9 GC of AAV8-TBG-hLCAT-V114M increases plasma CER in LCAT
KO/hApoAI transgenic mice while AAV8-TBG-hLCAT-WT does not. We measured
plasma lipids in AAV injected mice. 6 weeks after injection, both AAV-hLCAT injected
groups had a plasma %CE within the normal range at approximately 60% (A). The AAVhLCLAT-V114M has significantly elevated CER while the WT group did not. WT hLCAT
and hLCAT-V114M were expressed equally as measured by plasma LCAT mass (C)
and RT-PCR (D). * indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and
**** indicates p<0.00005 relative to AAV-Null injected mice. Errors bars indicate standard
error.
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Table 3. Plasma lipids in two FLD patients.

70

Figure 13. hLCAT-V114M reduces LpX in FLD patient plasma. We measured whole
plasma cholesterol esterification rate (CER) in plasma of two LCAT deficient
patients to confirm LCAT deficiency (A). 3H labeled FLD patient plasma was
incubated with transfection media containing equal concentrations of either WT- LCAT or
LCAT-V114M, or transfection media from control GFP transfection. After a 15 hour
incubation at 37C, we separated free cholesterol and cholesterol ester via TLC. (B) Total
percent cholesterol esterified in each sample after incubation, measured by scintillation
counting of 3H label in FC and CE bands. (C) Incubated plasma was fractionated by
FPLC. Curves show percent of total counts per fraction for each sample. The peak at
fraction 10 represents lipoprotein X (LpX), the peak at fraction 24 represents LDL and
the peak at fraction 39 represents HDL. (C,D and E) FPLC fractions across each peak
were pooled and then free cholesterol and cholesterol ester were separated by TLC.
Bars represent % of total counts present in each FPLC peak. VLDL peak corresponds
with lipoprotein X (LpX). Black bars indicate % of counts in esterified cholesterol for that
peak. * indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates
p<0.00005 relative to controls. Errors bars indicate standard error.
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Figure 14. Activity of hLCAT-V114 variants correlates with amino acid size. We tested the
activity of 20 hLCAT variants on rHDL, each with a different amino acid at position 11 (A). Activity
of the variants was variable, but when we plotted the relationship between molecular weight of
the amino acid and activity of the variant, we saw there was a strong correlation (B) with
tryptophan being an outlier. If we remove this outlier and replot the relationship, we measure a
correlation of 0.97 (C). Comparatively, if we plot the relationship between hydrophobicity index
and activity we see no correlation (D). * indicates p<0.05, ** indicates p<0.005, *** indicates
p<0.0005 and **** indicates p<0.00005 relative to WT. Errors bars indicate standard error.
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Figure 15. Molecular dynamics simulation of hLCAT-V114M. Image showing the
crystal structure of LCAT submerged in a water box, ready for simulation (A). Line graph
showing change in root-mean-square-deviation (RMSD) stabilization over the 10 ns
simulation time (B). Black line represents WT-LCAT, red line represents LCAT-V114M.
We then plotted the root-mean-square fluctuation (RMSF) of each residue of WT human
LCAT and LCAT-V114M over 10ns simulation (C) in order to compare the predicted
structures.
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Figure 16. Molecular dynamics simulation of hLCAT variants suggests V114M may
increase flexibility of the lid loop. (A) Image showing the location of V114M within the
LCAT structure. (B)Image showing the active site lid-loop. Lid loop is shown in light blue.
The catalytic triad/ active site is labeled in green. V114M is labeled in red. (C) we plotted
the delta-RMSF for each residue of LCAT-V114M relative to WT hLCAT. We highlighted
the five regions of hLCAT that are most dramatically affected by the V114M mutation.
(D) Close-up of delta-RMSF plots showing selected LCAT-114 variants. The five
numbered panels represent the highlighted regions in 16B. Center panel (number 3)
shows the delta-RMSF values in the lid loop region.
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Figure 17. Codon optimized hLCAT variants significantly increase plasma lipids in
BL6 mice. We designed four codon optimized variants of human LCAT, v1, v11, v26,
and v201,and expressed them in AAVs. We injected C57/BL6 mice (N=4) with one of
two doses of these vectors, AAV8-TBG-hLCAT (WT) or AAV8-TBG-Null then measured
plasma lipids out to 6 weeks post-injection. We measured total cholesterol (A), HDL-C
(B) and calculated % cholesterol esterified (C). * indicates p<0.05, ** indicates p<0.005,
*** indicates p<0.0005 and **** indicates p<0.00005 relative to AAV-Null injected mice.
Errors bars indicate standard error.
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Figure 18. Codon optimized hLCAT variants significantly increase plasma lipids in
LCAT KO mice. We designed four codon optimized variants of human LCAT, v1, v11,
v26, and v201,and expressed them in AAVs. We injected LCAT KO mice (N=7) with
1e10 GC of one of these new vectors, AAV-hLCAT (WT) or AAV-Null then measured
plasma lipids out to 8 weeks post-injection. We measured total cholesterol (A), HDL-C
(B), and calculated non-HDL cholesterol (C) and % cholesterol esterified (D). * indicates
p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates p<0.00005
relative to AAV-Null injected mice. Errors bars indicate standard error.
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CHAPTER 3: DEVELOPING A MURINE MODEL OF RENAL DISEASE IN LCAT
DEFICIENCY
Abstract
Chronic kidney disease with progression to renal failure is the most serious
clinical consequence of FLD and the primary reason for a need for novel therapies.
However, LCAT KO mice do not spontaneously develop renal disease and it has been
difficult to induce renal disease in LCAT KO mice. I examined in detail three potential
mouse models of FLD renal disease, with the goal of identifying an optimal model for
testing our AAV-TBG-hLCATV114M clinical candidate. In the first, I tested the effect of a
high fat/high cholesterol (HF/HC) diet in LCAT KO mice. HF/HC diet induced LpX in
LCAT KO mice, but did not induce renal disease. In the second, I performed unilateral
nephrectomy and then treated mice with the HF/HC diet, but saw no evidence of the
mice developing renal disease. In the third, I used LCAT KO/SREBP1a transgenic mice
where the SREBP1a transgene was driven by the PEPCK promoter and fed the mice a
high protein diet to induce expression of the SREBP1a. I did note that this model
resulted in a significant increase in urine albumin:creatinine ratios (ACR) indicative of
renal disease. However, when I injected AAV-hLCAT in these mice compared with
control vector, I saw no reduction in the ACR, even when the vector was given in
advance of starting the high protein diet. Despite my efforts, I conclude that the optimal
preclinical model for testing the efficacy of AAV-hLCAT on renal disease is not yet in
hand. Ω
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Introduction
The demonstration that a therapy has a clinical benefit, particularly regarding the
primary cause of morbidity and mortality for the disease of interest, is a critical step in
pre-clinical development. Chronic kidney disease with progression to renal failure is the
most serious clinical consequence of FLD and the primary reason for a need for novel
therapies. While the LCAT KO mouse model recapitulates the clinical plasma lipid
aspect of FLD, it notably lacks a spontaneous kidney phenotype analogous to FLD renal
failure 115. In order for a mouse model to be appropriate for the testing of the therapeutic
benefit of AAV gene therapy for renal failure in the setting of LCAT deficiency it should
have a robust renal phenotype consistent with the human disease, and develop this
phenotype by a mechanism comparable to the human patients’ renal failure 116,117. The
goal of the research outlined in this chapter was to establish a reliable mouse model of
FLD renal failure such that we can test the effect of our candidate AAV vector on the
primary cause of morbidity and mortality in this disease. Before outlining the studies
performed in this regard, we will first review previous relevant work.
As renal disease, in some form, is a feature of many complex metabolic disease,
mouse models of renal disease are widely used and diverse in their mechanisms

118
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Some common renal disease mouse models include the ⅚ nephrectomy, hypertension
induced by diet, diabetes or treatment with angiotensin and various autoimmune or
immune complex models 119. C57BL/6 mice are known to be especially resistant to
developing renal disease, and when studying renal failure on a C57BL/6 background, it
is often required to have a combination of stresses in order to induce a reliable
phenotype 120,. Hypertension is commonly combined with other factors as unilateral
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nephrectomy 121. Unilateral nephrectomy alone does not cause disease in most animals,
including mice and humans, if they are otherwise healthy. Compensatory regulation by
the remaining kidney is sufficient to counter the loss of renal tissue.
In 2001, Lambert et al. published a report of their mouse model of FLD in the
Journal of Biological Chemistry. The researchers created a genetically elaborate mouse:
the LCAT KO/LDLr KO/Apolipoprotein E KO and CETP transgenic mouse 122. This
mouse was meant to closely resemble the metabolic setting of human LCAT deficiency
such that the researchers could study the mechanisms of atherosclerosis in FLD. After
16 weeks on Paigen HF/HC diet, mice displayed many of the characteristics of the
human disease that are not seen in LCAT KO mice on standard chow diet. The mice
developed normochromic normocytic anemia and corneal opacities, consistent with the
human disease. While the animals consistently developed these two features, only a
subset of mice developed LpX, albuminuria and glomeruosclerosis. It is not understood
why only some mice developed renal disease, but this is the first report of a mouse
model with a phenotype similar to that of human FLD. For our research, we chose not to
use this model because of the cumbersome number of genetic manipulations: a total of
seven genetically altered alleles. The effect of the LDLr KO and ApoE KO together
cannot be ignored; both of these genetic manipulations have a dramatic effect on
plasma lipids and together they create a highly atherogenic phenotype, even in an LCAT
competent setting. The ApoE KO mouse has decreased HDL-C and dramatically
increased VLDL-C and develops atherosclerotic lesions even on a standard chow diet
123

. It has been shown that these mice can also develop renal lesions without the

addition of HF/HC diet or additional genetic manipulations. In short, we would not
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necessarily expect LCAT gene replacement to correct the renal disease phenotype in
these mice due to the confounding effects of the other factors. In addition, only a subset
of mice developed renal disease, and if one wishes to study the effect of gene therapy
on renal disease it is certainly preferable to have a fully penetrant phenotype.
A second mouse model of FLD renal disease was published in 2004 by Zhu et al.
of Dominic Ng’s lab. LCAT KO mice were crossed with human sterol regulatory element
binding protein 1a (SREBP1a) transgenic mice 124. SREBP1a is a transcription factor
that upregulates a number of genes in the cholesterol and fatty acid synthesis pathways.
SREBP1a transgenic mice do not have elevated plasma lipids but do accumulate lipids
in the liver, leading to marked hepatomegaly, and also have altered glucose metabolism.
Zhu et al showed that when the SREBP1a transgenic mouse is crossed with an LCAT
KO mouse, these mice accumulate VLDL sized lipoproteins, including some LpX-like
vesicles. On chow diet, these mice develop albuminuria and mild glomerulosclerosis by
about 6 months of age. Despite the encouraging success of this model, we chose not to
use this model for our studies because of the amount of time required to develop the
phenotype. A 6 month wait is not feasible for the pre-clinical testing of a therapeutic that
will require many sequential iterations, as information gained from each experiment is
incorporated into the next.
Our goal in this chapter is to establish a reliable mouse model of FLD renal
failure that is appropriate for the testing of gene therapy.
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Results
HF/HC Paigen Diet in LCAT KO Mice
For our first experiment, we chose to test the effect of HF/HC Paigen diet on
plasma lipids and renal function in LCAT KO mice. 8-10 week old mice (mixed males
and females) were started on Paigen HF/HC diet. Blood and urine was collected from
mice every four weeks to measure plasma lipids and urine albumin: creatinine ratios.
While C57BL/6 mice had no significant changes in their plasma total cholesterol and
HDL-cholesterol LCAT KO mice accumulated plasma cholesterol and phospholipids over
the course of the 16 week experiment (Figure 19 A-D). After 16 weeks on Paigen diet,
LCAT KO mice had an average total cholesterol of 596 mg/dL while control mice
remained comparable to baseline at 200 mg/dL (Figure 19A). HDL-C was stable over
time in C57BL/6 mice while it steadily increased in LCAT KO mice over time, from 4±1
mg/dL at baseline to 48±13 mg/dL after 16 weeks on diet (Figure 19B). The pattern of
phospholipid accumulation was similar, with control mice stable at around 200 mg/dL
and LCAT KO mice ranging from 82±4 mg/dL at baseline to 585±56 mg/dL after 16 weeks
(Figure 19D). This accumulation of lipids is consistent with the accumulation of

Lipoprotein X, which is primarily composed of phospholipids and free cholesterol.
To confirm the accumulation of LpX, we measured LpX-cholesterol in pooled
plasma samples collected before and after starting Paigen diet. LpX was separated from
other lipoproteins using MgCl2 and phosphotungstic acid and then total cholesterol was
measured in the resuspended isolate (Fig 20A). No LpX-cholesterol was detectable in
pooled plasma from C57BL/6 mice at any time point, and no LpX cholesterol was
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measured in LCAT KO samples while maintained on standard chow diet. However, LpX
cholesterol was detected in all pooled plasma samples after starting Paigen HF/HC diet,
and increased with time on diet, consistent with plasma lipids measured in individual
mice. After 16 weeks on Paigen diet, in pooled plasma samples we measured 38mg/dL
of LpX-C. A subset of LCAT KO mice were maintained on Paigen diet for 35 weeks, at
which point we measured nearly 100 mg/dL of LpX-C in pooled plasma samples. Bile
acids also accumulated in the blood of LCAT KO mice over time, while plasma bile acids
were not statistically different from baseline in C57BL/6 mice (Figure 20B). We also
separated pooled plasma samples by FPLC and measured total cholesterol in the
fractions (Figure 20C). While C57BL/6 mice have a prominent HDL peak at fraction 39,
LCAT KO mice do not have any measurable HDL-cholesterol. Instead, LCAT KO mice
have two cholesterol peaks, one in the VLDL range at fraction 5, and one broad peak,
from fractions 8-23, roughly the size of a large LDL. We believe that this peak at fraction
5 represents LpX, as the size is consistent with previously published literature, and the
area of the peak roughly corresponds with LpX-C measurements in pooled samples at
those timepoints. The broad peak in the LDL range appears to be an abnormal LDL,
which is also seen in human FLD patients.
I showed that LCAT KO mice accumulate plasma cholesterol and develop LpX
when fed HF/HC Paigen diet, but we wished to examine renal disease in these mice. So
First, we measured urine albumin: creatinine ratios (ACR) in mice 16 weeks after starting
Paigen diet, and compared ACRs measured in LCAT KO and C57BL/6 mice maintained
only on chow diet. There were no significant changes in urine ACR in any mice in this
experiment (Figure 21A). We also measured plasma creatinine in these mice and saw
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no significant difference between C57BL/6 and LCAT KO mice (Fig 21B). Plasma
creatinine was elevated in both strains 8 week after initiation of the diet, but returned to
baseline by 16 weeks. Despite no changes in renal function based on our biochemical
measurements, we fixed kidney tissue for histology for analysis. Because mesangial
hypercellularity is a feature of FLD renal failure and is relatively easily quantified by
microscopy, we quantified the average number of mesangial cells per glomerulus in our
experimental mice (Figure 21C). We found that although the difference was small, LCAT
KO mice did have a statistically significant increase in mesangial cellularity. Lastly, we
measured cholesterol accumulation in the kidneys. We measured total cholesterol, free
cholesterol, phospholipids and triglycerides and saw no significant trend across groups.
Relative to baseline, kidney cholesterol was significantly elevated in C57BL/6 mice after
16 weeks on Paigen diet, but was not significantly elevated in LCAT KO mice (Figure
21D). Overall, there was no evidence of renal dysfunction in these mice.

Unilateral nephrectomy combined with HF/HC Paigen diet in LCAT KO mice
Because we did not any signs of renal dysfunction in LCAT KO mice when on
HF/HC diet despite the accumulation of lipids and the appearance of LpX, we believe
that this phenotype is simply not damaging enough to overcome the natural resistance of
C57BL/6 mice to kidney fibrosis and renal failure. Therefore, we decided to add a renal
mass reduction to our existing model, in an attempt to overcome this resistance. We
hypothesize that the removal of one kidney will be sufficient to cause renal failure in
LCAT KO mice maintained on Paigen HF/HC diet. LCAT KO and C57BL/6 mice
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underwent surgery two weeks before beginning Paigen diet. Experimental mice
underwent a unilateral nephrectomy, the removal of one kidney, while control mice
underwent a sham surgery. Animals were given two weeks to recover and then were
started on HF/HC diet. Again, we measured plasma lipids and urine ACR every four
weeks. Consistent with our previous experiment, LCAT KO mice accumulated plasma
total cholesterol, HDL-cholesterol and phospholipids over time, while C57BL/6 mice did
not (Figure 22A-C). No plasma lipids were significantly different between the sham and
nephrectomy groups in either C57BL/6 mice or LCAT KO mice. Percent plasma
cholesterol esterified was also not different between sham and nephrectomy groups
(Figure 22D).
To examine the renal disease phenotype in these mice we weighed the kidney
tissue from each mouse at tissue collection and calculated kidney weight as a
percentage of body weight. If there is significant lipid accumulation and/or fibrosis we
would expect to see kidneys with a higher percentage of total body weight relative to
healthy animals. We did not see any statistically significant differences in kidney weight
in any of these animals (Figure 23A). Similar to the previous experiment, urine albumin:
creatinine ratios also showed no evidence of renal dysfunction in these mice, with the
mean ACR of each group ranging from just 20 to 60 μg/mg (Figure 23B).

LCAT KO/SREBP1a mice on high protein diet
As we did not have any success producing a mouse with a renal disease
phenotype in our first experiments, we moved on to another model, the LCAT
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KO/SREBP1a mouse. This mouse develops renal dysfunction by about 6 months of age
even if maintained on standard chow diet. However, we deemed this timeline to be
impractical for our purposes. In these mice, the SREBP1a transgene is under the
control of the phosphoenolpyruvate carboxykinase (PEPCK) promoter which can be
upregulated via high protein consumption. Unpublished data from our collaborators (not
shown here) suggests that high protein diet does indeed accelerate the progression of
renal disease in these mice.
To replicate the result from our collaborators, I set up a pilot experiment, to first
evaluate renal dysfunction in these mice, and then subsequently evaluate the effect of
AAV-hLCAT on renal disease. I started 8-10 week old male LCAT KO/SREBP1a
transgenic mice (N=3) on the high protein diet. One week after starting the diet (before
AAV injection), there was a substantial increase in the ACR, from 50 ug/mg at baseline
to roughly 800 ug/mg one week later (Figure 24F). This is a substantial increase in urine
ACR and is indicative of renal disease. At this point, one week after starting the diet, we
injected mice with 1e10GC of either AAV-hLCAT-WT or AAV-Null to examine the effect
on the progression of renal disease. I collected urine samples from mice every week to
assess the effect of AAV-hLCAT on urine ACR.
When we measured plasma lipids in these mice, we saw that in LCAT KO mice,
total cholesterol remained close to baseline while in null injected mice total cholesterol
increased (Figure 24A). This results is to be expected, as cholesterol rapidly
accumulates in LCAT KO/SREBP1a mice, even on chow diet. HDL-C was higher in Null
injected mice although not statistically significant (Figure 24B). FC and phospholipids
both increased in mice in the first week after starting high-protein diet, consistent with
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previously published literature and the accumulation of LpX (Figure 24C and 24D). Both
FC and phospholipids dropped after injection in mice that received AAV-hLCAT, but did
not drop in null injected animals. Percent plasma CE was normalized at around 65% in
AAV-hLCAT injected mice, indicating that the AAV-hLCAT injection was effective, but
remained at baseline of less than 20% in the null control group (Figure 24E). Despite
the normalization of plasma %CE due to LCAT expression, there was no difference in
urine ACR between hLCAT and null groups. The ratio in both groups increased rapidly
from 50 ug/mg at baseline to over 1000 ug/mg after 4 weeks on high-protein diet (Figure
24F). This indicates further progression of renal disease from weeks one to four, with no
indication of a positive effect of AAV-hLCAT.
We hypothesized that the damage induced by the high-protein diet may be too
strong to see reversal of the phenotype after AAV injection. Therefore, we performed a
second ‘prevention’ experiment in which we injected chow-fed male LCAT KO/SREBP1a
mice with 1e10 GC of AAV-hLCAT or AAV-Null (N=4). Four weeks after injection mice
were started on high protein diet and then urine and plasma samples were collected
every two weeks thereafter. In this experiment, plasma lipids were somewhat
comparable to the previous experiment, although more variable. There were no
statistically significant differences in plasma lipids including TC, HDL-C, FC and
phospholipids (Figures 25A-D) between AAV-hLCAT and AAV-Null injected mice.
However, the % CE was normalized in hLCAT injected mice at approximately 60%,
indicating effective LCAT expression, and remained near baseline in Null mice (Figure
25E). Disappointingly, urine albumin: creatinine ratios were not significantly different
between the two groups. For reasons that are not clear, they did not rise to the high
86

levels we saw in the previous experiment, with the peak ACR in this experiment being
around 800 μg/mg after 4 weeks on diet as compared to nearly 2000 μg/mg in the
previous study (Figure 25F).
Discussion
HF/HC diet induces LpX but not renal failure in LCAT KO mice
When we examined the effect of HF/HC Paigen diet on C57BL/6 and LCAT KO
mice, we found that C57BL/6 mice were relatively unaffected while LCAT KO mice
accumulated cholesterol and phospholipids in the plasma, consistent with the human
disease presentation and consistent with accumulation of LpX. The isolation of
cholesterol in LCAT KO plasma by MgCl2 and phosphotungstic acid supports the idea
that this accumulation is indeed LpX, and additionally, FPLC demonstrates the presence
of an abnormal VLDL range lipoprotein in these mice. Also, we can see by FPLC that
LCAT mice on Paigen diet do not have an HDL peak despite having HDL-C measured
by AXCEL. The Trinity Biotech HDL reagent we use for the measurement of HDL-C in
plasma using AXCEL, uses an ApoB antibody that precipitates all cholesterol contained
on ApoB lipoproteins (i.e LDL and VLDL) and then reacts with the cholesterol that
remains in the sample after the precipitation. In the case of LpX, which does not contain
ApoB, LpX cholesterol would be measured as HDL-C when using this reagent. This is
consistent with the measurement of LpX-C in pooled plasma samples, as the cholesterol
concentrations measured by these two methods are similar, with the Trinity Biotech
reagent measuring 45 mg/dL of HDL-C in LCAT KO mice and MgCl2/phosphotungstic
acid extraction measuring 42 mg/dL of LpX-C. Altogether, we conclude that these mice
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do in fact develop LpX is fed HF/HC diet.
Despite the increase in LpX, we did not find any evidence of renal failure in these
mice. The only measure that was significantly different between LCAT KO mice and
control mice was the number of mesangial cells per glomerulus, with the difference
being only 5 cells on average. Despite being statistically significant (p=0.03) this
difference is very small and almost negligible. Mesangial hypercellularity is a general
inflammatory reaction in the kidney and in this case might be a very early sign of some
damage. In any case, the phenotype in these mice is so mild that we chose not to
pursue this as a model for testing of gene therapy. Particularly for the testing of the
effect of different doses, a mild phenotype is unlikely to be sensitive enough to show the
small differences we would expect between groups.

Unilateral nephrectomy has no effect in LCAT KO mice on HF/HC diet
Despite developing LpX, we did not see any overt indications of renal failure in
LCAT KO mice when fed HF/HC diet. C57BL/6 are known to be resistant to kidney
fibrosis and renal failure and can be difficult to use as a model of kidney failure. We
chose to add a unilateral nephrectomy on top of the HF/HC Paigen diet in LCAT KO
mice, in the hope that this would overcome any natural resistance to disease. However,
we did not see any effect of the nephrectomy on either LCAT KO or control mice. It is
possible that this is still due to the inherent resistance of C57BL/6 mice, that
nephrectomy combined with diet is simply not enough to overcome it. However, it is also
possible that we have not accurately recapitulated the disease mechanisms that exist in
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human patients with FLD. Despite having LpX, perhaps the amount of LpX may not
enough to cause significant damage.

AAV-hLCAT has no effect on renal disease in LCAT KO/SREBP1a mice
We tested our AAV-hLCAT vector in LCAT KO/SREBP1a mice on high protein
diet in two ways, injected either after or before the institution of the high protein diet.
The high-protein diet successfully induced renal damage as measured by elevated urine
ACR, but injection with AAV-hLCAT did not reverse this effect. AAV-hLCAT mice did
have normal plasma %CE indicating that the AAV injection and expression of hLCAT
was successful. When we injected AAV-hLCAT after starting the diet, despite successful
expression of LCAT, there was no difference in urine ACR between the AAV-hLCAT
injected mice and the AAV-Null injected mice. We hypothesized this may be because the
damage induced by the diet occurred prior to injection and may have been too severe to
be reversed. However, we also did not see any slowing of the progression in LCAT
injected mice relative to the null group, suggesting that the disease process is still
continuing even in the presence of LCAT. Indeed, when we injected mice with AAVhLCAT before beginning high protein diet, even though the AAV-hLCAT injected mice
normalized their plasma %CE indicating successful treatment of the LCAT deficiency,
there was no difference in urine ACR between the two groups. It is possible that we did
not see an effect of hLCAT in these mice because of the small number of animals used
and the large variation in plasma lipids, due both to the transgene and the AAV-injection.
And although the dose of 1e10 GC normalizes plasma %CE and raises HDL-C to near
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normal levels in LCAT KO mice, perhaps this dose is not high enough to prevent the
excessive accumulation of LpX that occurs in this model.
Conclusions
The development of therapeutics for FLD has faced the obstacle of the lack of a
mouse model that recapitulates the renal failure phenotype seen in human patients.
Without an animal model it is difficult to study the potential impact of therapeutics on
disease development and progression. Here we investigated three different mouse
models of FLD renal failure. Firstly, we found that LCAT KO mice on HF/HC diet
developed LpX but did not have any signs of renal failure. When we combined a
unilateral nephrectomy with HF/HC diet in LCAT KO mice, we found that unilateral
nephrectomy had no impact and did not worsen the phenotype. Third, we examined
LCAT KO/SREBP1a mice on high protein diet. We successfully induced renal failure in
these latter mice as measured by substantial increases in urine ACR. However, when
we tested our AAV-hLCAT, we found it had no effect on ACR in these mice. More work
is required to develop a reproducible preclinical model of renal disease in FLD.
However, it is possible that AAV-hLCAT could be advanced into the clinic on the basis of
the compelling normalization of the plasma lipids and %CE even without clear evidence
of impacting on the renal disease.
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Materials and Methods
Paigen Diet Model
LCAT KO mice were maintained on chow diet until 8 weeks of age at which point
in time they were started on an equivalent of Paigen’s Atherosclerotic Diet from
Research Diets (#D12336). This diet is 16% fat (12.5% cholesterol), 46% carbohydrate
and 21% protein by weight, with 5% sodium cholate Before beginning the diet, blood
was collected via retro-orbital bleed and 4 hour urine samples were collected each day
for three days, using metabolic cages, for measurement of urinary albumin:creatinine
ratios (ACR). Blood was collected every four weeks. 16 weeks after starting the diet,
mice were euthanized and liver and kidneys were harvested for analysis. Urine albumin:
creatinine ratios were measured using the Albuwell M Murine Microalbuminuria ELISA
kit from Exocell-Glycadia and the matching picric acid based Creatinine Companion kit.
ACR was measured in each urine sample and then a mean was calculated for each
mouse across the three day period. At harvest, kidneys were dissected into quarters.
Two quarters of each kidney were frozen for RNA extraction. The two remaining quarters
were stored in 4% PFA to be prepared for histology. After drying of tissue using
sequential ethanol washes tissues were mounted in paraffin blocks, sectioned and
stained with
Unilateral Nephrectomy Model
Male LCAT KO mice maintained in our facility underwent surgery at
approximately 8-10 weeks of age. Mice were anesthetized with Ketamine/Xylazine
combination. Experimental animals had the left kidney removed, while in control animals,
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an incision was made and then sutured, but both kidneys were left intact. Animals were
monitored closely during recovery, given subcutaneous saline and were given a daily
dose of Acepromezine for pain management through day four. Animals were allowed to
recover for two weeks post-surgery and then were started on Paigen diet, as done
previously. Similarly, blood samples were collected every 4 weeks as well as urine
samples, three days in sequence for each time point. Animals were euthanized 16
weeks after surgery at which point the liver and remaining kidney were collected for
analysis.
LCAT KO/PEPCK-SREBP1a Model
LCAT KO/ human sterol regulatory element binding protein 1a transgenic (LCAT
KO/SREBP1a) breeders were transferred from the National Institutes of Health from the
lab of Alan Remaley and then bred in house. Mice are as described in Zhu et al 124.
These mice have the SREBP1a transgene under control of the PEPCK promoter, which
can be upregulated using high protein diet 125. Only male mice who tested positive for
the SREBP1A transgene were used in experiments. Before beginning high protein diet,
blood samples were collected via retro orbital bleed and urine samples were collected
using metabolic cages. Again, for each time point, 4 hour urine samples were collected,
three days in a row, and the ACR values for each mouse were averaged across those
three days for the given timepoint. Urine samples were collected weekly and blood
samples were collected bi-weekly. In our first experiment using these mice, animals
began high protein diet and then we're injected with a single dose of AAV one week
later. In our second experiment, mice were injected with a single dose of AAV first, and
then began high protein diet one week later. In both experiments, Null vector was used
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in a control group and AAV was given via IP injection at a dose of 1e10 GC per mouse.
Plasma LpX-C Measurement
Plasma samples were stored at -80C. After thawing on ice, 150 ul of pooled
plasma was mixed with an equal volume of phosphotungstic acid solution (PTA): 80g/L
phosphotungstic acid with 10 mM EDTA, to precipitate HDL. The samples were mixed
by inverting 5 times and then incubated for 10 minutes on the benchtop. The samples
were then centrifuged at 2,000xg for 10 minutes and then the supernatant, containing
LpX was moved to a new tube. LpX was then precipitated using two times the volume of
200 mM magnesium chloride (MgCl2) in Tris HDL buffer, pH 9.0. Samples were mixed
well, again by inverting 5 times, incubated on the benchtop for 10 minutes and then
centrifuged for 10 minutes at 2,000xg. The supernatant, containing LDL and VLDL, was
removed and the pellet was resuspended in 150 μl of PBS with 0.05% SDS. Total
cholesterol was measured in the samples using the Wako Total Cholesterol reagent as
done previously.
Other Methods
Other methods such as measurement of plasma lipids and LCAT mass, CER
assay and FPLC were all performed as described in Chapter II unless otherwise stated.
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Figure 19. LCAT KO Mice on Paigen HF/HC diet accumulate plasma cholesterol and
phospholipids. Groups of LCAT KO and C57BL/6 mice (N=15) were maintained on high fat/high
cholesterol (HF/HC) Paigen diet. Plasma was collected from mice before starting the diet and
every 4 weeks thereafter until the animals were euthanized 8, 12 or 16 weeks later. LCAT KO
mice accumulated plasma total cholesterol (A), HDL-C (B), non-HDL-C (C) and phospholipids (D)
over the course of the experiment, whereas control mice did not.* indicates p<0.05, ** indicates
p<0.005, *** indicates p<0.0005 and **** indicates p<0.00005 relative to baseline. Errors bars
indicate standard error.
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Figure 20. LCAT KO mice on HF/HC Paigen Diet accumulate lipids consistent with
LpX. We measured LpX cholesterol in pooled plasma samples (A) and plasma bile acids
in individual plasma samples (B) collected from C57BL/6 and LCAT KO mice maintained
on HF/HC Paigen diet. Additionally, we fractionated pooled plasma samples from each
group by FPLC and measured total cholesterol in fractions (C). * indicates p<0.05, **
indicates p<0.005, *** indicates p<0.0005 and **** indicates p<0.00005 relative to
baseline. Errors bars indicate standard error.
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Figure 21. No evidence of renal dysfunction in LCAT KO mice on HF/HC Paigen Diet. We
maintained 15 LCAT KO mice and 15 C57BL/6 mice on paigen diet and euthanized 5 mice at
each at 8 weeks, 12 weeks and 16 weeks starting the diet for tissue collection. We collected 4
hour urine samples from these mice every 4 weeks. Shown here are the urine albumin: creatinine
ratios (ug/mg) for each group (A). We also measured plasma creatinine (B). Using kidney
sections stained with H&E we quantified the number of mesangial cells per glomerulus, to assess
mesangial cellularity (C). Lastly, we measured total cholesterol content of homogenized kidney
(D). * indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates p<0.00005
relative to C57BL/6 control mice . Errors bars indicate standard error.
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Figure 22. Unilateral nephrectomy does not affect plasma lipids in LCAT KO mice on
Paigen diet. C57BL/6 and LCAT KO mice underwent unilateral nephrectomy or sham surgery
and two weeks later were started on Paigen diet. Plasma samples were collected every 4 weeks
after starting the diet and mice were euthanized at 16 weeks. We measured plasma total
cholesterol (A), HDL-cholesterol (B) and phospholipids (C). We also calculated plasma %CE (D).
* indicates p<0.05, ** indicates p<0.005, *** indicates p<0.0005 and **** indicates p<0.00005
relative to baseline. Errors bars indicate standard error.
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Figure 23. No evidence of renal dysfunction in LCAT KO mice on Paigen diet after
unilateral nephrectomy. We measured kidney weight in all animals during tissue
collection and calculated % of body weight (A). As done previously, we collected urine
samples every 4 weeks and measured urine and albumin to calculate urine albumin:
creatinine ratios (ACR) (B). Errors bars indicate standard error.
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Figure 24. AAV-hLCAT does not reverse renal failure in LCAT KO/SREBP1a mice
on high protein diet. 8-10 week old male LCAT KO/SREBP1a mice were fed high
protein diet. 1 week after starting the diet mice were injected with 1e10GC of AAVhLCAT-WT. Plasma samples were collected prior to starting the diet and prior to
injection and 1,2 and 4 weeks after injection. In plasma samples we measured total
cholesterol (A), HDL-cholesterol (B), free cholesterol (C) and phospholipids (D). We
calculated % plasma cholesterol esterified (E) and urine albumin: creatinine ratios to
examine renal function (F). * indicates p<0.05, ** indicates p<0.005, *** indicates
p<0.0005 and **** indicates p<0.00005 relative to baseline. Errors bars indicate standard
error.
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Figure 25. AAV-hLCAT does not prevent renal failure in LCAT KO/SREBP1a mice on high
protein diet. 4 weeks before starting high protein diet mice, were injected with 1e10GC of AAVhLCAT-WT. 8-10 week old male LCAT KO/SREBP1a mice were fed high protein diet. Plasma
samples were collected prior to starting the diet and prior to injection and 1,2 and 4 weeks after
injection. In plasma samples we measured total cholesterol (A), HDL-cholesterol (B), free
cholesterol (C) and phospholipids (D). We calculated % plasma cholesterol esterified (E) and
urine albumin: creatinine ratios to examine renal function (F). * indicates p<0.05, ** indicates
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p<0.005, *** indicates p<0.0005 and **** indicates p<0.00005 relative to baseline. Errors bars
indicate standard error.

CHAPTER 4: MOVING TOWARD THE CLINIC FOR AAV-hLCAT AS A THERAPY FOR
FLD

The scope of the work in this dissertation was designed to complete essential
steps needed in order to proceed to the testing of AAV gene therapy for FLD in a human
clinical trial. We tested a range of doses of AAV-hLCAT in two mouse models in order to
understand the relationship between dose, plasma LCAT mass and plasma lipids. From
this work we can estimate the initial doses for the first clinical trial. Second, we leveraged
human genetic studies to identify the first gain-of-function variant of human LCAT and
we demonstrated this gain-of-function is consistent across in vitro assays, in vivo testing
in two animal models and ex vivo in human plasma. Furthermore, very little literature
exists comparing multiple codon optimized variants side by side. Here we compared four
codon optimized variants of human LCAT and found little difference between these
variants and WT LCAT. Lastly, we examined three different mouse models of FLD renal
failure, two of which failed to produce a renal failure phenotype, and a third in which we
tested our AAV-hLCAT, which unfortunately had no effect on disease in these mice.
Despite this, using the information gained in these studies, we believe that there is a
strong case to move forward with IND-enabling studies of our clinical candidate, with the
plan to file an IND and proceed with a Phase I/II clinical trial.
Here we performed the first studies of AAV-hLCAT as a therapeutic for FLD. We
tested a total of five doses of AAV-hLCAT in LCAT KO mice and three doses in
‘humanized’ LCAT KO/hApoAI transgenic mice. For the purpose of these studies, we
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defined the MED, or minimally efficacious dose, as the dose that produced statistically
significant increases in plasma %CE. We believe that a normal %CE is likely to be
therapeutic and is easily measured, therefore making it a good endpoint for our studies.
We found that the MED in LCAT KO mice was 1e10 GC per mouse which is
approximately equivalent to 5e11 GC per kg. The MED was reduced in LCAT
KO/hApoAI transgenic mice, to 3e9 GC per mouse or 1.5e11 GC per kg. This dose is
more than ten fold lower than the lowest dose used in recent AAV gene therapy trials for
hemophilia B 126, which was 2e12 GC per kg.
Next, we tested the in vitro activity of three LCAT variants that exist in the human
population at measurable levels. All three of these variants were found to be significantly
associated with differential HDL-C levels in the human population in the heterozygous
state. These associations, identified in people carrying a single variant allele in
combination with a normal allele, suggest that the effect of these SNPs on the function of
the enzyme is relatively strong. Strong enough to overcome the effect of the normal
allele. We found that in the case of two of these variants, R123H and V114M, the activity
of these variants on recombinant HDL was consistent with their human lipid
associations. Activity of the third variant, S232T was not found to be significantly
different from WT, although the activity of this variant in general, was much more
variable. It is possible that the mechanism by which this variant is associated with
decreased HDL-C is not related to its enzymatic activity. However, when we further
examined the V114M variant, which had a positive association with HDL-C, we found
that it not only had increased activity in vitro,at 160% of WT, but also in vivo, supporting
that the increase in activity of this variant is responsible for its positive association.
When we expressed this gain of function variant of hLCAT using AAV2/8, we
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found that V114M, because of its increased activity, reduced the MED of the vector in
both LCAT KO and LCAT KO/hApoAI mice. The use of V114M instead of WT hLCAT,
reduced the MED from 1e10 GC per mouse to 3e9 GC per mouse in LCAT KO mice,
and in LCAT KO/hApoAI mice, we concluded the MED was reduced from 3e9 GC per
mouse to 1e9 GC per mouse. This dose of 1e9 GC per mouse is equivalent to 5e10 GC
per kg, a dose that is 20 fold lower than the approved dose of Glybera and 40 fold lower
than the lowest dose used in the Hemophilia B trial. As we mentioned previously, when it
comes to gene therapy, the lower the dose, the better. A lower dose reduces the risk of
immune reactions against the vector and the transgene, as well as reduces the burden
on production and price of the vector, which under good-manufacturing practice (GMP)
can be quite expensive. This low dose is a promising start in the world of gene therapy
for FLD.
In these studies, we sought to apply the theory of codon optimization to improve
the effectiveness of our our vector. The study of 48 codon optimized variants of TrCBH2
by Mellitzer et al. in 2014, demonstrated wide variation in the expression of the gene
from these different sequences. Some variants had almost undetectable expression,
while others had expression nearly double that of the WT sequence 127. One other study,
which compared three codon optimized variants of mating factor α prepro-leader,
showed that all three variants improved expression of the gene, sometimes as much as
four fold 128. In contrast, we found that codon optimization had minimal impact on the
effectiveness of our vector to increase plasma lipids and %CE, but that once variant,
hLCATv1, did appear to be slightly better than WT. We will examine plasma LCAT mass
and transcript levels in these mice to determine id codon optimization has improved the
transcript: protein ratio.
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In the studies presented here, we tested three different mouse models of human
FLD. We found that HF/HC diet, although it induced the formation of LpX in LCAT KO
mice, and not control C57BL/6 mice, it did not induce renal failure. We hypothesized that
this was due to the inherent resistance of C57BL/6 mice to kidney fibrosis and renal
disease. When we combined unilateral nephrectomy with HF/HC Paigen diet, we again
found that this had no impact on renal function in these mice. Lastly, we did show that
high protein diet did successfully induce rapid increases in urine ACR, in some cases as
much as a 40 fold increase in less than four weeks, in LCAT KO/SREBP1a mice.
However, treatment with AAV-hLCAT did not prevent or reverse this effect. We believe
that we did not see an effect of AAV-hLCAT in these mice because either, the dose of
AAV we used was too low or, more likely, that the mechanism of disease in these mice
is not LCAT dependent.
We failed to establish a reproducible mouse model of FLD renal disease that is
appropriate for the testing of AAV-hLCAT, as we initially set out to do. However, we have
gained essential knowledge about what doesn’t work. This knowledge can be hard to
come by, as the outcome of these ‘failed’ experiments, is most often not published and
not publicly available. It is quite possible that others have attempted similar studies in the
past and seen the same result. However, the bias towards the publication of positive
results means that we do not have access to this information unless we happen to
connect with the investigators who performed the study. In the world of science today,
this is an everyday reality and an essential part of research, and we shall move forward
from here with a better idea of what to try next. We could try the LpX injection model that
was recently published by Ossoli et al 129.
Although demonstrating an effect on the key source of clinical morbidity in a
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preclinical model is desirable before progression to clinical testing, it may not always be
necessary, particularly if sufficient efficacy using other relevant endpoints can be
demonstrated. This is particularly true for orphan disease therapeutics, as the Orphan
Disease Act gives special consideration, and the requirements for preclinical efficacy are
somewhat more flexible, with the intention to compensate for the unique issues
surrounding the development of therapies for rare disease 130. Thus, moving forward in
this program may be feasible even without hard data that this approach reduces renal
disease in a mouse model of FLD. Recombinant LCAT enzyme therapy was able to
proceed to clinical trials without an animal model of renal failure, and given the similarity
in strategy, we expect that we will be able to do the same.
Based on our results, our next step is to combine our gain of function LCAT,
hLCAT-V114M with the codon optimized variant, hLCATv1. We anticipate that the
combination of these two factors may produce a vector that is even more effective than
hLCAT-V114M. We will repeat dosing studies using this new vector and infer a starting
dose for the clinical trial.
Recombinant enzyme therapy was shown to reduce renal dysfunction in an
LCAT deficient patient 131. This important finding suggests that FLD renal disease is
potentially reversible upon the introduction of functional LCAT. If we can achieve a
comparable plasma concentration of hLCAT using our AAV, it is reasonable to expect
that our vector would improve or eliminate renal dysfunction perhaps even more
effectively than recombinant enzyme therapy, as the plasma hLCAT concentration will
be more stable. In this patient, a recombinant hLCAT dose of 9 mg/dL normalized
plasma %CE and the effect lasted for several days after each infusion. The peak plasma
concentration of LCAT following the infusion of this dose was approximately 4 times that
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of the normal human plasma concentration, but the steady state plasma LCAT mass
was approximately 120% of normal. The middle dose tested in this patient was 3 mg/dL.
This dose had a steady state plasma LCAT concentration comparable to a normal
individual and produced near normal %CE during the several days following infusion.
We have shown that using AAV-hLCAT-V114M, we can reach a plasma LCAT
concentration near normal, at approximately 80%, and produce normal %CE, using just
3e9 GC per mouse, or 1.5e11 GC per kg of vector. We would expect that the therapeutic
dose of our vector may be even lower than this, perhaps 5e10 GC per kg as we
concluded in our studies, as the expression of hLCAT from the AAV genome will be
constant and plasma concentrations will be stable, unlike with recombinant enzyme
therapy.
An additional advantage of gene therapy over recombinant enzyme therapy, is
the reduction in risk of immunity against the LCAT enzyme. Repeated treatments with
recombinant enzyme comes with means the development antibodies against the
enzyme is inevitable. The level of antibodies must be monitored and managed
throughout the life of the patient to ensure the success of treatment. Of course, the
possibility of developing antibodies against the enzyme is still a risk with gene therapy,
but with only a single immunization event, the risk is much reduced. However, this risk is
especially high in patients with null mutations, and so the management of patients using
immune suppressants will always be a reality, even with gene therapy.
Our work lays the foundation for a clinical trial testing AAV mediated gene therapy for
FLD. The dream of gene therapy is achievable for FLD, as it is for and many other
diseases that are in the development pipeline, including hemophilia and familial
hypercholesterolemia. Unfortunately, there are many more rare diseases that have not
106

been so well studied and/or are not good candidates for gene therapy. Additionally, the
financial obstacles of gene therapy remain a great concern. The ability of the
pharmaceutical and biotech industries to support the production and sale of such a
specialized product is limited, as the number of patients for each disease is small and
the financial investment to develop such a product is astronomical. However, if the
successes of AAV gene therapy can continue, if we, as researchers in the field of gene
therapy, continue to pursue further investigation of the advantages, disadvantages and
mechanisms of this versatile gene transfer platform, particularly in human patients, there
is hope that this platform may be applicable to many other rare diseases as well.
Increasing popularity of AAV as a therapeutic platform will drive new ideas and new
expertise surrounding these important issues, and clinical trials of AAV gene therapy will
be essential in demonstrating the feasibility and flexibility of this strategy as a therapeutic
approach, driving the popularity of the AAV platform as a whole.
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